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ABSTRACT 
 
Properties of a Dehydroalanine Analog of Glutathione: A Reactive Electrophilic Busulfan 
Metabolite 
 
Cody J. Peer 
 
Gamma-Glutamyldehydroalanylglycine (EdAG) is a dethiolated, electrophilic metabolite of 
glutathione (GSH) derived from the Phase II conjugation of GSH with busulfan catalyzed by 
glutathione S-transferase (GST).  It was demonstrated in this dissertation that EdAG could be 
successfully synthesized and shown to be a metabolite of busulfan from in vitro metabolism by 
enzymes in human liver cytosol.  The electrophilic EdAG was reactive toward the cellular thiols 
cysteine and glutathione (GSH), and toward cysteine residues in reduced bovine insulin B-chain 
and bovine serum albumin in vitro, as well.  EdAG was demonstrated to be a reversible 
noncompetitive inhibitor of GSTs, specifically GSTA1-1 at micromolar concentrations up to 1 
mM.  EdAG at high concentration (10 mM) was found to be an irreversible inhibitor of human 
GSTA1-1, although an EdAG-modified peptide was not observed.  Inhibition of GST by a 
busulfan metabolite has the potential of altering busulfan pharmacokinetics or GSH cellular 
function.  Since conversion of GSH to EdAG represents a loss of thiol-related redox properties 
and the gain of a captodative radical scavenging dehydroalanine group, the reactivity of EdAG 
with hydroxyl radical was evaluated.  EdAG was shown to scavenge hydroxyl radical generated 
in the Fenton reaction in a concentration-dependent manner.  The results indicate a stabilized 
carbon-based captodative radical intermediate in the reaction of EdAG with hydroxyl radical.  In 
support of a captodative mechanism was the identification of a dimerized γ-glutamylserylglycine 
as a product in the reaction.  Conversion of GSH from a redox active nucleophile to an 
electrophilic dehydroalanine is a significant change in chemical reactivity that may have 
biological implications for GSH and free radical biochemistry as well as busulfan therapeutics.  
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Introduction 
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1.1 Drug Metabolism 
 Nearly all complex organisms have built-in mechanisms for eliminating foreign 
compounds, or xenobiotics.  Typically, the objective is to make those xenobiotics more water 
soluble in order to be eliminated.  Involved in these processes are a variety of enzymes, 
substrates, and co-factors.  The structure and properties of the xenobiotic determines the 
metabolic pathway that will metabolize the compound, however any single xenobiotic isn’t 
necessarily limited to one specific pathway.  There are two major routes, or phases, of 
metabolism that is dependent on the xenobiotic involved.  Each phase employs certain enzymes, 
cofactors, and substrates to make the xenobiotic more polar and thus eliminated. 
 Phase I metabolism usually occurs in the liver or gut lumen, where xenobiotics are 
subjected to oxidation, reduction, or hydrolysis by enzymes such as the cytochrome P450 
(CYP450) superfamily of enzymes and flavin monooxygenases (FMOs).  There are a variety of 
metabolic mechanisms used to make the xenobiotic more polar and prepare it for elimination or 
further metabolism.  The phase I-mediated mechanisms include, but are not limited to, side chain 
oxidation, aromatic ring oxidation, methyl oxidation, heterocyclic ring oxidation, N-dealkylation, 
O-dealkylation, S-dealkylation, deamination, N-oxidation, sulfoxidation, and azoreduction.   
 Phase II metabolism has the same basic function as phase I, that being to make the 
xenobiotic more polar to eliminate it from the organism.  Phase II metabolism can occur on 
either a previously unmetabolized xenobiotic or one that underwent phase I metabolism.  Phase 
II metabolic processes include, but are not limited to, glucuronidation, sulfation, acetylation, and 
conjugation with the abundant endogenous cellular nucleophilic tripeptide, glutathione (GSH).   
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1.1.1 Phase II Conjugation with Glutathione 
 Phase II conjugation of xenobiotics with GSH is the result of catalysis by the glutathione 
S-transferase (GST) superfamily of enzymes.  The addition of glutathione to endogenous or 
xenobiotic hydrophobic electrophiles render those adducts more water-soluble and thus, more 
readily eliminated from the body.  Glutathione adducts are also subject to cellular efflux and 
further metabolism by the Mercapturic acid pathway, leading to polar cysteine-S-conjugates.  
There are many different sub-families of the GSTs based on their subcellular localization as 
either membrane-bound, mitochondrial, or cytosolic.  Nomenclature of the different classes of 
GSTs is based on Greek letters (e.g. alpha, pi, mu), but abbreviated with Roman capital letters 
(e.g. A, P, M) (1).  The membrane-bound classes of GSTs include three isoforms: microsomal I, 
microsomal II, and leukotriene C4 (LTC4), that are structurally very different from their cytosolic 
counterparts (2).  Not much is known about these three classes of GSH transferases, however 
they are nonetheless important in detoxification of certain electrophilic compounds.  The 
cytosolic classes of GSTs have been studied much more extensively and thus more structural and 
mechanistic information is known.  The classes of the soluble (cytosolic) GST isoforms that are 
known include, but may not be limited to if new classes have since been discovered, alpha, zeta, 
theta, mu, pi, sigma, and omega (3).   
 The genetic origin has been extensively studied to determine the similarities between the 
classes of the GST superfamily of enzymes.  GST isoforms of the same class (e.g. alpha) are 
classified together because their genes are located in very close proximity to each other on the 
same chromosome (3).  GSTs are also dimeric proteins, but can only dimerize with isoforms 
within the same class.  For example, the human GST alpha class (hGSTA) contains two major 
isoforms, hGSTA1 and hGSTA2.  Between these two isoforms, three different dimeric proteins 
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can form; the homodimeric hGSTA1-1 and hGSTA2-2, or the heterodimeric hGSTA1-2.  The 
genes for each isoform is written italicized, e.g. hGSTA1.   
 Most of the seven soluble classes of GSTs have been crystallized and their quaternary 
and secondary subunit structures revealed.  Cytosolic GSTs are all slightly different in terms of 
their primary amino acid sequence and tissue abundance, but all have similar protein folding and 
overall quaternary structure.  The C-terminal domain accounts for two thirds of the protein 
structure and consists mostly of alpha helices (2).  One of the major structural differences among 
the soluble GST classes is the substrate specificity for the electrophilic substrate to be conjugated 
by GSH.  The hydrophobic substrate binding site, or H-site, is structurally unique for each 
isoenzyme within each class.  The H-site is located within the crevice that forms between the N-
terminal domain I and the C-terminal domain II.  The N-terminal domain consists of mixtures of 
α-helices and β-sheets and account for the remaining one third of the overall protein structure.  
Cytosolic GSTs all serve the same purpose of conjugating GSH to electrophilic substrates, thus 
all soluble GST classes need to bind GSH.  Domain I contains similar secondary structural 
features across cytosolic GST classes because this accounts for the GSH binding site, or G-site.  
There are some differences in domain I between the classes in terms of the GSH recognition 
residues among classes and species, namely different residues responsible for docking and 
activating the GSH in the G-site.  Most GST classes utilize a tyrosine residue positioned near the 
docked GSH to form hydrogen bonds to the thiol to deprotonate and stabilize the thiolate.  Only 
theta class GSTs utilize a serine residue to hydrogen bond GSH (4).  In human GSTA1-1, Arg15 
and Tyr9 both form hydrogen bonds to the thiol of GSH when docked in the G-site (5).  This 
helps lower the pKa of GST-bound GSH from 9 to about 6.6 (6).   
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1.2 Glutathione 
 Glutathione (GSH) is an abundant cellular tripeptide consisting of L-glutamic acid, L-
cysteine, and glycine.  It is present in millimolar concentrations intracellularly and in micromolar 
concentrations in plasma and urine.  It is the major source of cysteine and thiols in animals and 
plants.  It is synthesized intracellularly, first by the rate-limiting addition of L-glutamate and L-
cysteine by the ATP-dependent γ-glutamylcysteine synthetase (7,8), followed by addition of 
glycine to the C-terminal end of γ-glutamylcysteine by the ATP-dependent glutathione 
synthetase (9).  The cysteine residue contains a reactive and nucleophilic thiol side chain (-SH).  
The major roles of glutathione, as they pertain to this dissertation research, are two-fold: as a 
cellular nucleophile to conjugate and detoxify electrophilic compounds (in reactions catalyzed by 
GSTs), and as a cellular redox agent that scavenges reactive oxygen species (ROS) (10).  Other 
roles of GSH include autoimmunity and transhydrogenation with compounds such as ascorbic 
acid (11).  Glutathionylation of proteins occurs during states of oxidative stress and is 
categorized as a redox mechanism involving GSH.  Often times, glutathionylated hemoglobin is 
a biomarker for oxidative stress (12).   
 Glutathione plays a major role in maintaining redox equilibrium in a cell.  During normal 
physiological conditions for yeast cytoplasm, there are low steady state levels of ROS, thus 
oxidative stress is low (13).  Most glutathione exists in the reduced form (GSH at pH 7.4, pKa 9), 
the levels of which are about 3000-fold more than the oxidized glutathione (GSSG) levels due to 
efficient reduction mechanisms (14).  Normal cellular functions of mitochondria, peroxisomes, 
and other physiological cellular oxidative process require the need for redox mechanisms for 
their constant removal.  There are many glutathione-dependent enzymes and mechanisms 
responsible for reduction of cytosolic ROS species, including GSH-dependent thiol peroxidases, 
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thioredoxin, and glutaredoxin (15).  Thioredoxin and glutaredoxin are primarily responsible for 
maintaining protein thiol oxidation in the cytosol.  Another enzyme, glutathione reductase (GR), 
plays a major role in cellular redox state by reducing the oxidized GSSG back to GSH for 
recycling and continued redox scavenging.  GR is a homodimeric enzyme containing FAD that 
requires NADPH for electron donation and is a very efficient reaction, with GSSG having a 
relatively low binding affinity (KM = 55 µM) considering the millimolar glutathione 
concentrations found intracellularly (16).   
 Phase II conjugation of xenobiotics with GSH is catalyzed by the GST superfamily of 
enzymes.  Among those xenobiotics that undergo this metabolism are numerous anticancer 
agents, specifically DNA alkylating agents, because they are electrophilic.  Compounds must be 
electrophilic in order to be conjugated by nucleophilic atoms on DNA nucleotides (e.g. N7 of 
guanine bases).  There are five classifications of DNA alkylating groups based on their structure 
and anticancer mechanism: nitrogen mustards, nitrosoureas, ethylenimines, triazenes, and alkyl 
sulfonates (17).  Of interest to this dissertation research was the alkyl sulfonate anticancer agent 
busulfan, due to its phase II GSH conjugation and resulting metabolite that is a dethiolated 
glutathione. 
 
1.3 Busulfan 
 Busulfan is a bifunctional anticancer agent that is classified as an alkyl sulfonate as part 
of the larger group of anticancer drugs known as DNA-alkylating agents.  Busulfan contains 
sulfonate groups on both ends of the molecule (Figure 1.3.1) that allow it to be reactive towards 
DNA on both ends.  The carbons adjacent to the electron-withdrawing sulfonate groups are 
electrophilic and are susceptible to nucleophilic attack.   
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Figure 1.3.1 Busulfan 
 
This allows either end of busulfan to be conjugated by nucleophilic atoms on DNA nucleotides, 
such as the N7 atom on guanine bases.  Busulfan was developed in the 1950s and first used 
clinically as a chemotherapeutic in 1959.  Initially, busulfan was used to treat chronic 
myelogenous leukemia (18,19) but is also now used in high doses along with cyclophosphamide 
for myeloablative conditioning therapy prior to bone marrow transplants and hematopoietic stem 
cell transplants (20), as well as polycythemia rubra vera (21) and essential thrombocythemia 
(22). 
 Busulfan is metabolized by phase II conjugation with GSH catalyzed by the GST 
superfamily of enzymes, but predominantly cytosolic GSTA1-1 in liver hepatocytes (23).  The 
hydrophobic busulfan, which is typically administered orally or through intravenous emulsion 
solutions, is a good substrate for the hydrophobic binding site (H-site) on GSTA1-1.  The 
product formed by GSTs, which is released back to the intrahepatocellular cytosol, is an unstable 
sulfonium ion (γ-glutamyl-β-[S-tetrahydrothiophenium]alanylglycine; GS+THT) (24).  It was 
shown by Younis et al that GS+THT slowly degrades at pH 7.4 by a base-catalyzed β-
elimination reaction of tetrahydrothiophene (THT), and the degradation occurs faster at pH 8.4 
(25).  The portion of GS+THT remaining after elimination of THT is a dethiolated analog of 
GSH, γ-glutamyldehydroalanylglycine (EdAG) as depicted in Scheme 1.1.   
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Scheme 1.1 Busulfan Metabolism Catalyzed by GSTA1-1 
 
EdAG contains a dehydroalanyl residue in lieu of the cysteinyl residue in GSH that potentially 
alters the chemical properties of the molecule.  The moiety of glutathione that enabled the 
molecule to have such important and wide-ranging functions, the nucleophilic thiol side chain on 
the cysteinyl residue, is now replaced with an electrophilic vinylic carbon.  Dehydroalanines are 
not a novel species, however much has already been studied including formation and occurrences 
in vivo. 
 
1.4 Dehydroalanines 
1.4.1 Formation of Dehydroalanines 
 Dehydroalanines are amino acid residues found within proteins or peptides.  They can be 
formed either naturally by cellular processes (e.g. post-translational modifications) or chemically 
(e.g. food processing).  Dehydroalanines (Dha) and dehydrobutyrines (Dhb) are mainly formed 
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from serine and threonine residues, respectively, by the same mechanism under conditions of 
high pH and temperature (26).  Dha residues formed from cysteine residues in vivo are rare aside 
from chemically-induced non-physiological reactions (27).   
 One such setting that provides these conditions is during food processing, where many 
proteins in meat and other processed foods contain cysteine residues that undergo a base-
catalyzed β-elimination induced by heat and/or the alkaline environment (28).  Another more 
naturally-occurring scenario where the dehydration of serine and threonine can occur is during 
an in situ alkaline environment, where basic amino acids near a serine or threonine could induce 
a β-elimination forming Dha and Dhb, respectively (29).  Posttranslationally-modified peptides 
made by ribosomes within Gram-positive bacteria contain many Dha or Dhb residues that can be 
further modified by nucleophilic addition by a cysteine residue to form a nonreducible 
lanthionine thioether (Ala-S-Ala).  Proteins that contain these lanthionines produced by 
ribosomes in Gram-positive bacteria have antibiotic properties and are referred to as lantibiotics 
(30).   
 
1.4.2 Lantibiotics are peptides that contain dehydroalanine crosslinks with cysteines 
 The 1928 discovery of a substance produced by a colony of bacteria that inhibited its 
further growth was the birth of lantibiotics (31).  Gram positive bacteria produce a variety of 
peptides called bacteriocins, of which those that contain lanthionine or β-methyl lanthionine 
crosslinks are called lantibiotics.  When lantibiotics are ribosomally synthesized and 
posttranslationally modified, numerous serines and threonines are transformed into 
dehydroalanine or dehydrobutyrine residues, respectively.  These serine/threonine residues are 
phosphorylated by serine/threonine kinases followed by dehydration by dehydratases and 
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cyclization with nearby cysteine residues (forming the lanthionine) by cyclases before 
proteolysis of the leader peptide (32).  Serines and threonines within the leader portion of the 
peptide are not subject to modification to Dha and Dhb, respectively, however within the 
propeptide portion, serines are twice as likely to avoid modifications as threonines (33).  The 
incidence of modification and cyclization are dependent upon the amino acids flanking the 
modified dehydrated amino acids.  It was determined that hydrophobic, nonaromatic amino acids 
more often flank serines and threonines that become modified (33).  Dha and Dhb can then react 
with cysteine residues flanked by less hydrophobic amino acid residues near the C-terminus 
within the same peptide to form the lanthionine or β-methyl lanthionine crosslinks, respectively, 
that are integral in the efficacy of the lantibiotic as an antimicrobial agent.  The thioether 
crosslinks that form the bridges are very important to the structural stability and antimicrobial 
efficacy of the lantibiotic (34,35).  The structural rigidity of lantibiotics is dependent upon the 
thioether rings, as well as the peptide’s resistance to proteolysis and heat, which are also ring-
dependent (36).  The LanB dehydratases are nonspecific concerning stereochemistry, but the 
LanC cyclases, in addition to the stereospecificity of the peptide sequence, play a role in 
determining ring formation (37-39).  Due to their stability and resistance to proteolysis, 
lantibiotics have not shown as much bacterial resistance as conventional antibiotics have.  
Lantibiotics could serve as a novel antibiotic for drug-resistant strands of bacteria.   
 Lantiobiotics are classified into two types, depending on their shape and functionality.  
Type A lantibiotics are typically amphiphilic and elongated peptides and target the cell 
membrane of bacteria to form pores that induces bacterial death (40).  Type B are globular 
proteins that bind to lipids in bacterial cell membranes that effectively halt production of 
membrane lipids by inhibiting the enzymes that produce them.  Lantibiotics are cationic peptides 
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that are effective in much lower concentrations than those cationic peptides typically 
manufactured by mammals, insects, fish, and amphibians (41).  Type A lantibiotics use LanB 
dehydratases and LanC cyclases to transform serine/threonine residues to Dha/Dhb, respectively, 
and type B lantibiotics use LanM proteins that execute the same reactions in type B lantibiotics 
as LanB and LanC enzymes for type A lantibiotics (42,43).  Based on the modes of action, which 
is determined by the type of lantibiotic (A or B), there are many lantibiotics that have potential in 
treating bacterial diseases like acne and MRSA (Nisin A, Lacticin 3147, Gallidermin, Epidermin, 
Mutacin 1140, Mersacidin, Actagardine) as well as inflammation (Duramycin) and regulation of 
blood pressure (Cinnamycin, Ancovenin) (44).   
 Nisin, the common food preservative, is the most known and studied lantibiotic.  Due to 
its antibiotic properties and structure that enable it to avoid proteolysis and thermal degradation, 
it is widely used to preserve such foods as vegetables, canned goods, dairy products, and natural 
cheeses (45).  Nisin contains many dehydroalanines that are not within thioether rings, thus they 
are susceptible to conjugation by nucleophiles outside of the peptide (e.g. glutathione).  It is not 
as potent in preserving meat because it is suspected that the high GSH content in meat tissue can 
form other thioethers with dehydro amino acids in the peptide (46).  Synthetic dehydroalanines 
occur in proteins of food during food processing due to the high temperature and alkali 
conditions. 
 
1.5 Research Objectives 
 Busulfan is known to be metabolized via GSTA1-1 catalyzed phase II glutathione 
conjugation to form the unstable sulfonium GS+THT.  The degradation product of the enzyme 
metabolized product, GS+THT, is the dehydroalanine analog of glutathione, EdAG (Scheme 1.1).  
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EdAG has been previously shown to bind GSTs (25).  The electrophilic nature of the 
dehydroalanine renders EdAG reactive towards cellular nucleophiles. Also, it was suggested that 
like other dehydroalanine-containing compounds, EdAG could also react with radicals, such as 
hydroxyl radical.  Thus, it was the focus of the research presented here to determine the 
following: 
1.  Identify EdAG as an in vitro product of busulfan metabolism with GSTs based on 
LC/MS characteristics compared to a synthesized EdAG standard. 
2.  Determine the reactivity of EdAG toward the cellular nucleophiles GSH and L-
cysteine, as well as cysteine residues in proteins using insulin and bovine serum albumin 
as model proteins. 
3.  Determine if EdAG is inhibiting GSTs and elucidate the mechanism of EdAG-induced 
inhibition of GSTs over a wide concentration range. 
4.  Characterize the radical scavenging activity of EdAG towards the ROS hydroxyl 
radical using electron paramagnetic resonance (EPR) spectroscopy and mass 
spectrometry.   
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Chapter 2 
 
Identification of EdAG as a metabolite from in 
vitro Busulfan-GSH conjugation catalyzed by 
GSTs 
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INTRODUCTION 
 
2.1.1 Busulfan 
 Busulfan, or 1,4-butanediol dimethanesulfonate, is a bifunctional DNA alkylating agent 
classified as an alkyl sulfonate.  Busulfan, like other alkylating agents, induces its effects by 
donating an alkyl group to nucleophilic biomolecules, such as DNA.  The mechanism of action 
of busulfan is to bind DNA in rapidly-dividing cells (e.g. cancer cells) to prevent replication.  
The primary site of action on DNA is the N7 atom on guanine nucleotides, although other atoms 
provide secondary sites of action.  Busulfan forms intrastrand cross-links at the 5’-GA-3’ 
sequence, as well as monoalkylation on the N7 of guanine, in a dose-dependent manner (1). 
 Busulfan was introduced in 1959 as a chemotherapeutic agent to treat myeloproliferative 
disorders.  Initially, busulfan was used to treat chronic myelogenous leukemia (2,3) but is also 
now used in high doses along with cyclophosphamide for myeloablative conditioning therapy for 
bone marrow transplants and hematopoietic stem cell transplants (4), as well as polycythemia 
rubra vera (5) and essential thrombocythemia (6). 
 
2.1.2 Busulfan Absorption, Distribution, Metabolism, and Elimination (ADME) 
 Busulfan pharmacokinetics have been extensively studied as the oral formulation, and 
only more recently studied as the intravenous (i.v.) formulation.  Busulfan disposition following 
oral dosing can best be described by a one-compartment open model.  Oral formulations were 
originally marketed as Myleran® by GlaxoSmithKline with relatively good bioavailability (mean 
80%), but varied greatly.  Recently, the organic solvent N,N-dimethylacetamide (DMA) has been 
used to solvate the highly lipophilic busulfan into aqueous solution for i.v. administration.  The 
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market name for the i.v. formulation is Busulfex® (Otsuka), and is composed of 6 mg/kg 
busulfan solvated in 33% DMA (v/v) and 67% polyethylene glycol 400 (v/v).  Each Busulfex® 
vial is then diluted further to a busulfan concentration of 0.5 mg/mL in 0.9% saline or 5% 
dextrose with a pH range of 3.4-3.9.  Comparisons of bioavailability and exposure between oral 
and i.v. formulations have shown that a 1 mg/kg oral dose is bioequivalent to a 0.8 mg/kg i.v. 
dose of busulfan (7).  There has been a recent switch in busulfan formulation usage from oral to 
i.v. because the intravenous route is easier to perform therapeutic drug monitoring to ensure 
busulfan exposure remains below the target level of 1,500 µM?min to avoid toxicity such as 
hepatic veno-occlusive disease (HVOD) (8).   
 Oral busulfan has very high interpatient pharmacokinetic variability that is affected by 
various conditions such as circadian rhythmicity, disease states, age, and dosage (9-12), with 
either a zero-order absorption (13) or first-order absorption (14,15).  Time to maximum 
absorption (tmax) range between 0.5-1 hour, however some patients can absorb busulfan 
immediately whereas others (up to 25%) have lag times of up to an hour (16).  Busulfan 
disposition is best described by a one-compartment open model.  Roughly 1% of busulfan is 
excreted in urine as unchanged (13).  Typical elimination half-lives did not vary significantly 
between children and adults, with average half-lives in children of 2.5 hours (17-19), and in 
adults of 2.75 hours (20).   
 Orally-administered busulfan is absorbed from the gastrointestinal (GI) tract into the 
hepatic portal circulation, where it undergoes first-pass metabolism from either the gut or liver, 
or both, prior to distribution into the systemic circulation.  GSTA1-1, the major enzyme 
responsible for busulfan metabolism, is mainly located in the liver but is also found in the 
intestinal wall epithelia.  The first-pass effect can ultimately lower the bioavailability of an oral 
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drug, thus decreasing its exposure and altering its pharmacokinetics.  In the systemic circulation, 
busulfan has a relatively low binding affinity to plasma proteins, where 32.4% of busulfan dose 
is irreversibly bound (21).  Intravenous busulfan avoids first-pass metabolism and thus exposure 
and clearance are not affected by this effect.  Busulfan is also evenly distributed between plasma 
and blood cells, where 46.9% of the busulfan dose was irreversibly bound to blood cells to 
induce a myeloablative effect (21).  A significant portion (20%) of busulfan is able to cross the 
blood brain barrier (22).  Busulfan concentrations in the cerebrospinal fluid were significant 
enough to be monitored and elimination parameters calculated (23-25). 
 The major route of busulfan metabolism is glutathione S-transferase (GST)-catalyzed 
GSH conjugation, which forms a relatively unstable sulfonium ion (γ-glutamyl-β-[S-
tetrahydrothiophenium]alanylglycine; GS+THT) (26).  The major GST isoform responsible for 
busulfan conjugation to GSH is the cytosolic GSTA1-1 (27).  The sulfonium is further 
metabolized by either of two pathways.  The first pathway is the Mercapturic acid pathway 
(MCA), where the sulfonium is cleaved by a variety of enzymes that produce the final product of 
a N-acetylcysteine-S-sulfonium conjugate (28).  The purpose of the MCA pathway is to detoxify 
toxic compounds, however the product of the second to last step of the MCA pathway is a 
cysteine S-conjugate.  This compound can either be N-acetylated with Acetyl CoA by N-
acetyltransferase, or can be a substrate for a class of enzymes called cysteine-S-conjugate β-
lyases.  These enzymes cleave the thioether linkage, forming a dehydrocystine (later rearranges 
to α-imino acid before hydrolyzing to pyruvate and ammonium) and a sulfur-containing moiety, 
that is potentially toxic when reabsorbed from the gut lumen or renal proximal tubule 
recirculation.  The second pathway that the GS+THT sulfonium can follow is through a 
nonenzymatic β-elimination of tetrahydrothiophene (THT) (26), which produces an electrophilic 
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dehydroalanine analog of glutathione, γ-glutamyldehydroalanylglycine (EdAG) (29) (Scheme 
1.1).   
 This dissertation will focus on the busulfan metabolite EdAG that is suggested to be 
reactive towards biological nucleophiles due the electrophilic dehydroalanine residue.  The 
potential reactivity of EdAG could be implicated in a number of disease states where GSH 
depletion or macromolecular conjugation is associated, such as hepatic veno-occlusive disease. 
 
2.1.3 Hepatic Veno-Occlusive Disease Associated with Busulfan 
 Hepatic veno-occlusive disease, or HVOD, is caused by the destruction of sinusoidal 
endothelial cells (SECs) resulting from myeloablative conditioning therapies of busulfan and 
cyclophosphamide during bone marrow and hematopoietic stem cell transplants.  Prior to 
therapeutic drug monitoring, anywhere between 30-50% of patients receiving busulfan 
conditioning therapy developed HVOD, with a third of those having such a severe form that they 
do not survive (16,30).  HVOD is difficult to predict because oral administration of busulfan has 
such a high interpatient variability in absorption and exposure.  In myeloablative therapy, 
busulfan is normally administered first, followed by a washout period of at least 24 hours, then 
treatment with cyclophosphamide.  Busulfan has been shown to deplete intracellular hepatic 
GSH levels in murine models by as much as 50% (31) and it is known that the major metabolite 
of the active form of the prodrug cyclophosphamide is detoxified by GSH, further depleting 
GSH.  Because both drugs require GSH for detoxification along with an oxidative environment 
that could saturate GR-catalyzed GSSG reduction to GSH, it is logical that intracellular hepatic 
GSH could be reduced to levels that are insufficient to protect the SECs in the liver.   
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 Busulfan causes a depletion in GSH stores due to its metabolism and renders hepatocytes 
and SECs vulnerable to injury caused by the co-administered cyclophosphamide.  It is uncertain 
whether HVOD is caused by toxicity related to circulating busulfan or from busulfan 
metabolites.  However, Srivastava et al suggested busulfan metabolites as responsible for GSH 
depletion and increasing the exposure of cyclophosphamide as a possible explanation for the 
elevated risk of HVOD (32).  Tetrahydrothiophene (THT) is the lipophilic metabolite of busulfan 
that undergoes further oxidation by Cytochrome P450s and has been shown to be toxic to SECs 
and hepatocytes, thus most research on busulfan-mediated HVOD has focused on THT.  Clinical 
trials involving busulfan-cyclophosphamide co-administration have found a correlation between 
busulfan exposure levels and HVOD that would suggest a maximum busulfan exposure (<1,500 
µmol x min/L) that greatly reduces chances of inducing HVOD (9).  Therapeutic drug 
monitoring after the first dose of busulfan is useful in determining busulfan exposure and allows 
for dose adjustments to reduce risks of HVOD. 
 Therapeutic drug monitoring requires bioanalytical instrumentation to identify and 
quantify busulfan and its metabolites in biological fluids in order to determine safe and effective 
dosing and exposure limits.  Typically, such instruments as high performance liquid 
chromatography (HPLC) coupled to electrospray ionization mass spectrometry (ESI-MS), or 
LC/MS, are employed.  HPLC is used to separate analytes from salts and other impurities in the 
matrix, while MS can structurally identify and quantify the analytes. 
 
2.1.4 Electrospray Ionization Mass Spectrometry (ESI-MS) 
 A common ionization technique used with mass spectrometry when interfaced with liquid 
chromatography is electrospray ionization (ESI), a soft ionization technique that ionizes analytes 
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in the solution phase before nebulization to the gaseous phase without degrading or denaturing 
the analyte (33).  ESI was first published by John Fenn in 1989 (34), but was the cumulative 
work of many.  The principles behind ESI were laid down by Lord Rayleigh in 1882, and then 
fully realized into production by Malcolm Dole in 1968, who discovered that when there are 
solubilized ions in a droplet, as the solvent evaporates and the droplet becomes smaller, the 
charge density increases to a critical point where the droplet disperses into numerous smaller 
droplets.  This phenomenon is known as the Rayleigh limit, where Coulombic repulsion was 
greater that surface tension and allowed the droplet to disperse into many tiny droplets (35).  The 
Rayleigh limit then applies to each offspring droplet and the process is repeated as the ionized 
droplets are “sprayed” from the narrow-bore capillary needle.   
 Electrospray ionization can be applied to both positive and negative ions, however 
positive ESI is more common due to the ability of nitrogen atoms to add protons, with the 
majority of marketed pharmaceuticals possessing amide and amine functional groups, where the 
oxygen atom of the amide is protonated.  In positive ESI, a positive charge, usually 5 kV, is 
applied to the cone and is usually called the cone or spray voltage.  This serves to help repel the 
positively-charged analytes in droplets away from the cone and towards the mass analyzer.  
There also exists a counter electrode with either a small orifice or heated capillary, where a 
negative charge of significantly lower voltage is applied to attract the cationic analytes.  An inert 
gas, usually nitrogen gas, is used as a sheath gas to desolvate the charged droplets on their way to 
the mass analyzer.   
 
2.1.5 ESI-MS with Ion Trap for structural analysis 
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 Ion trap (IT) mass analyzers are commonly used in conjunction with ESI to separate and 
analyze ions according to their mass to charge ratio (m/z).  First invented in the 1950s, ITs are 
about the size of a softball and contain three electrodes, where an entrance and exit electrode 
surround a ring electrode.  Together, these three electrodes apply a constant radio frequency (RF) 
signal with steadily increasing amplitude along with a direct current (DC) to the ring electrode.  
This forces the ions into an orbit that essentially “traps” the ions, with each ion traveling on its 
own orbit according to its m/z ratio.  Due to the kinetic energy associated with the ions, a 
damping gas (typically helium) is applied in the ion trap to cool the ions to a stable oscillating 
flight path or trajectory.   
 IT mass analyzers have the ability to eject all ions out of the mass analyzer except the ion 
of interest, which can then be subjected to collision-induced dissociation (CID) by bombardment 
with high energy helium atoms.  Tandem mass spectrometry, or MS/MS, is frequently used to 
study the structure of molecules.  IT mass analyzers also have the ability to perform multi-stage 
fragmentation (MSn), capable of fragmenting the same ion numerous cycles. 
 
2.1.6 Chapter Goals 
 It has been logically assumed that EdAG is a degradation product of the major busulfan 
metabolite resulting from Phase II conjugation to GSH catalyzed by glutathione S-transferase, 
specifically isoform A1-1.  When busulfan is metabolized by GSTA1-1, a sulfonium ion is 
formed, γ-glutamyl-β-(S-tetrahydrothiophenium)alanylglycine, or GS+THT, that is unstable at 
pH 7.4 and non-enzymatically degrades to THT and EdAG.  While most research has focused on 
THT, there is a lack of literature on EdAG as a metabolite from busulfan.  Thus, it was desired in 
this chapter to demonstrate that EdAG is a metabolite from GST-catalyzed busulfan conjugation 
27 
 
with GSH using an in vitro model of human liver cytosol.  First, a reference standard of EdAG 
will be synthesized to better identify the compound formed under physiological reaction 
conditions using LC/MS/MS. 
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EXPERIMENTAL PROCEDURES 
 
2.2.1 Materials 
 Glutathione, 1-chloro-2,4-dinitrobenzene (CDNB), secondary butanol, busulfan, L-
cysteine, formic acid, DMSO, Tris buffer, pH 7.4, and Dowex-50W were purchased from Sigma-
Aldrich (St. Louis, MO).  Sodium bicarbonate, methanol (optima), acetonitrile (optima), 
isopropyl alcohol, and hydrochloric acid were purchased from Fisher Scientific (Pittsburgh, PA).  
All water used was deionized with a NANOpure® water purification system (Barnstead, San 
Jose, CA).  Pooled human liver cytosol (HLC) from multiple donors, containing all cytosolic 
isoforms of GST (20 mg/mL total protein concentration) was purchased from BD Gentest 
(Bedford, MA).  All water used was deionized with a NANOpure® water purification system 
(Barnstead, San Jose, CA). 
 
2.2.2 Instrumentation 
 High-performance liquid chromatography (HPLC) was performed on a Shimadzu 10 Avp 
binary pump HPLC system equipped with a UV/Vis detector (Shimadzu Scientific Instruments, 
Columbia, MD).  Mass spectrometry was performed using an electrospray ionization (ESI) ion 
trap (IT) LCQ DECA (ThermoFisher Scientific, Waltham, MA), capable of multi-stage mass 
spectrometry (MS, MS/MS, MS3).  Structural information was obtained using nuclear magnetic 
resonance (NMR) on a Varian 300 MHz broadband spectrometer (Varian, Palo Alto, CA). 
 
2.2.3 Synthesis of γ-Glutamyldehydroalanylglycine (EdAG) 
2.2.3.1 Synthesis of the Precursor S-(2,4-dinitrophenyl)-Glutathione (GS-DNB) 
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 EdAG was synthesized by the elimination of S-(2,4-dinitrobenzene) from S-(2,4-
dinitrophenyl)glutathione (GS-DNB).  Thus, GS-DNB was first synthesized by the condensation 
of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB) under basic conditions 
based on a modified method from Patchornik (36).  Equimolar solutions of GSH (3.07 g in 40 
mL of 1 N NaHCO3; 10 mmol) and CDNB (2.02 g in 20 mL methanol; 10 mmol) were prepared 
and CDNB was added dropwise to GSH over 30 minutes with stirring.  The solution was stirred 
at room temperature for one hour and then filtered to eliminate precipitates.  The product was 
precipitated from solution by addition of 1 M HCl and collected by vacuum filtration, dried 
overnight in a vacuum desiccator, and recrystallized from hot water.  To ensure the correct 
product was obtained, the yellow crystals were characterized by ESI-MS (m/z 474), MS/MS (m/z 
399, MH+-glycine; m/z 345, MH+-pyroglutamic acid), melting point analysis (m.p. 189-191 ˚C) 
and 1H NMR in d6-DMSO.  The following 1H NMR resonances were monitored: δ 1.84 (m, 1H), 
1.95 (m, 1H), 2.32 (m, 2H), 3.31-3.38 (m, 2H), 3.60-3.65 (m, 1H), 3.73 (m, 1H), 4.61 (m, 1H), 
7.97 (d, 1H), 8.46 (d, 1H), 8.71 (d, 1H), and 8.87 ppm (m, 2H). 
 
2.2.3.2 Synthesis of EdAG from GS-DNB 
 S-(2,4-Dinitrophenyl)glutathione was used as a precursor to γ-
glutamyldehydroalanylglycine (EdAG) based on a modified method from Carthew et al (37).  
Two grams of GS-DNB were dissolved in 100 mL of 0.5 M NaOH and stirred for 30 minutes at 
room temperature.  To remove impurities, the solution was extracted with 40 mL butanol and 
repeated a total of 5 times.  The combined aqueous layers were diluted to 300 mL and 
approximately 15 grams of activated Dowex®-50W ion exchange resin (hydrogen form) was 
added to remove sodium ions.  The Dowex® was activated by dissolving the resin in 1 M HCl 
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and dried.  The pH of the solution dropped from 13 to 3.0, indicating exchange of H+/Na+.  The 
aqueous solution was evaporated using either roto-evaporation or speed vacuum evaporation to 
collect a light brown solid.  The obtained product was characterized by LC/MS/MS by the 
observance of a single absorbance peak at 254 nm corresponding to parent ion m/z 274 that was 
fragmented (MS/MS) to obtain characteristic daughter ions (m/z 256, MH+-water; m/z 199, MH+-
glycine; m/z 145, MH+-pyroglutamic acid).  1H NMR in D2O was also performed and the 
following peaks were monitored: δ 2.06 (m, 2H), 2.48 (m, 2H), 3.69 (m, 1H), 3.93 (s, 2H), and 
5.76 (d, 2H).  LC/MS/MS conditions performed were as follows: A Thermo Hybercarb column 
(100 x 2.1 mm I.D., 5 µm, ThermoFisher, Waltham, MA) was used to isolate the product from 
other constituents in the reaction mixture.  A gradient of mobile phase A (0.5% formic acid in 
90/10, v/v, water/acetonitrile) and mobile phase B (0.1% formic acid in 50/50, v/v, 
isopropanol/methanol) at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 
minutes, 0→50% B; from 7-9 minutes, 50→0% B; and from 9-15 minutes, 100% A.  An ESI ion 
trap mass spectrometer was operated in the positive ion MS/MS mode with a spray voltage of 5.2 
kV, capillary voltage of 30 V, capillary temperature of 300 ºC, a nitrogen sheath gas flow rate of 
80 arbitrary units, and a selected reaction monitoring on m/z 274 (± 1.5 amu) with 30% collision 
energy. 
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Scheme 2.1 Synthesis of EdAG from GSH and CDNB 
 
 
2.2.3.3 Formation of EdAG from S-Nitrosylated GSH (GSNO) 
 GSNO has the potential to degrade into EdAG by the elimination of S-NO (S-nitric 
oxide).  This could serve as a more efficient precursor to EdAG than GS-DNB without the 
hydrophobic impurities.  The stability of GSNO under various pH conditions was assessed with 
the hypothesis that at high pH, the GSNO will lose S-NO and EdAG will remain.  Controls of 
GSH, NEM (trap GSH for more stable signal in LC/MS), and EdAG were incubated for 24 hours 
in a 37 °C water bath in 100 mM Tris buffer, pH 8.4.  Aliquots were taken every hour for the first 
six hours, then again at 24 hours to determine baseline changes in stability using LC/MS, with 
GS-NEM serving as an internal standard.  Then, GSNO and NEM were incubated over 24 hours 
and samples analyzed the first 5 hours and then again at 24 hours.  The decrease in GSNO signal 
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relative to EdAG was monitored to determine extent of GSNO degradation to EdAG.  The 
presence of GS-NEM indicates that GSNO degraded to GSH, which was trapped by NEM.  If 
GSNO was degrading to EdAG, the ratio of GSNO/EdAG would decrease.  LC/MS in the 
positive electrospray single ion monitoring mode was used to determine relative quantities of the 
ions m/z 433, m/z 337, and m/z 274, corresponding to GS-NEM, GSNO, and EdAG, respectively.  
Chromatographic separation was achieved using a gradient of mobile phase A (0.5% formic acid, 
0.1% trifluoroacetic acid in water) and mobile phase B (0.1% formic acid, 0.1% trifluoroacetic 
acid in 50/50, v/v, methanol/water) as follows: 0→15 min, 0→40% B; 15→17 min, 40→100%; 
and 17→20 min, 100→0% B.  A Thermo Hybercarb column (100 x 2.1 mm I.D., 5 µm, 
ThermoFisher, Waltham, MA) was used to separate the constituents in the incubation with a flow 
rate of 200 µL/min.  The first mass spectral scan event employed two simultaneous single ion 
monitoring (SIM) scans of m/z 274 (for EdAG) and m/z 337 (for GSNO) and was performed 
from 0→12 min.  The second scan event was a single SIM on m/z 433 (for GS-NEM) from 
12→20 min. 
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Scheme 2.2 Synthesis of EdAG from GSNO 
 
2.2.4 Identification of EdAG after in vitro busulfan metabolism 
Busulfan (0-5 mM) was incubated with human liver cytosol (total protein 1.0 mg) in the 
presence of 1.0 mM GSH in 100 mM Tris buffer (pH 7.4, total volume 1.0 mL).  Busulfan was 
dissolved in DMSO and the total DMSO concentration was less than 1.0% (v/v).  The mixture 
containing human liver cytosol and GSH in buffer was preincubated for 5 minutes in a water 
bath maintained at 37 °C, and reactions started by the addition of busulfan.  Changes in the levels 
of GSH, the enzymatic product GS+THT, EdAG, and a nonreducible lanthionine thioether GSG 
(from GSH conjugation to EdAG) were monitored by liquid chromatography-mass spectrometry 
(LC/MS).  Chromatographic separation of the polar compounds was achieved using a Thermo 
Hypercarb column (100 x 2.1 mm I.D., 5 µm particle size) (ThermoFisher, Waltham, MA).  A 
gradient of mobile phase A (0.5 % formic acid in 90/10, v/v, water/acetonitrile) and mobile 
phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol) at 0.2 mL/min was run from 0-5 
minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9 minutes, 50→0% B; and from 9-
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15 minutes, 100% A.  The following ions were monitored: m/z 308, m/z 362, m/z 274, and m/z 
581, corresponding to reduced GSH, GS+THT, EdAG, and GSG respectively.  The structure of 
EdAG was confirmed using LC/MS/MS in a separate run that fragmented m/z 274 to monitor 
product ions of m/z 256, 199, and 145, consistent with neutral losses of water, glycine, and 
pyroglutamic acid, respectively, based on a comparison of the mass spectrum and retention time 
of the metabolite with that of the chemically synthesized standard. The structure of GSG was 
also confirmed in a separate LC/MS/MS.. 
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RESULTS 
 
2.3.1 Synthesis of γ-Glutamyldehydroalanylglycine (EdAG) 
 EdAG was successfully synthesized from GSH and CDNB according to the method of 
Asquith and Carthew (37) modified by Younis et al (29).  Typical product yields of the 
precursor, S-(2,4-dinitrophenyl)glutathione (GS-DNB), ranged from 54-85% after 
recrystallization.  ESI-MS was performed to confirm product identity by monitoring the 
molecular ion m/z 474 (Figure 2.3.1).  Tandem mass spectrometry (MS/MS) was also performed 
for structural identification and the product ions of m/z 345 and m/z 399 were formed, 
corresponding to the MH+ GS-DNB molecular ion with neutral losses of pyroglutamic acid and 
glycine, respectively (Figure 2.3.2).   
 
Figure 2.3.1 ESI-MS of GS-DNB 
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Figure 2.3.2 MS/MS of GS-DNB 
 
EdAG was then synthesized from GS-DNB by addition of 0.5 M NaOH to induce a base-
catalyzed β-elimination of the 1-S-(2,4-dinitrobenzene), followed by purification steps.  Typical 
yields ranged from 5-20%.  The structure of EdAG was determined first by proton nuclear 
magnetic resonance (1H NMR) in deuterium oxide (D2O), where the two vinylic protons of the 
dehydroalanine moiety resonate as a doublet at 5.76 ppm (Figure 2.3.3).  The resulting 1H NMR 
spectrum is comparable to previous spectra that were fully characterized (29).  
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Figure 2.3.3 1H NMR of EdAG 
 
The purity of EdAG was determined by LC/MS/MS, where the presence of a single peak in both 
the UV254nm absorbance and the MS/MS spectrum suggested EdAG is the major constituent 
present (inset of Figure 2.3.4).  Tandem mass spectrometric (MS/MS) structural confirmation 
was determined on the EdAG ion at m/z 274 that produced the daughter ions m/z 145, m/z 199, 
and m/z 256, corresponding to the MH+ EdAG molecular ion with neutral losses of pyroglutamic 
acid, glycine, and water, respectively (Figure 2.3.4).   
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Figure 2.3.4 LC/MS/MS Identification of EdAG 
 
 
2.3.2 Formation of EdAG from S-Nitrosylated GSH (GSNO) 
 EdAG synthesis could occur via an alternate mechanism by the potential loss of S-nitric 
oxide (S-NO) from S-nitrosylated glutathione (GSNO).  S-Nitrothiols are stable carriers of nitric 
oxide (NO), of which S-nitrosylated glutathione is one of the most abundant.  S-
Nitrosoglutathione, or GSNO, is capable of transporting NO as well as transporting GSH to 
induce such reactions as protein S-nitrosylation and S-glutathionylation (38).  S-Nitrosylated 
proteins are formed from transnitrosylation of NO from GSNO to cysteine residues on proteins.  
S-Glutathionylation of proteins could be formed from degradation of GSNO to EdAG, through 
the loss of S-NO, and subsequent conjugation of EdAG by a cysteine residue.  The 
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aforementioned chemical synthesis of EdAG involved removal of hydrophobic impurities 
resulting from the 1-S-(2,4-dinitrobenzene) moiety that has relatively poor yield.  It was 
hypothesized that GSNO could lose S-NO to form EdAG under similar alkaline conditions in a 
much cleaner synthesis procedure with potential higher product yields.  The stability of GSNO 
was determined by incubation for 24 hours in a 37 °C water bath in Tris buffer, pH 8.4, which 
were optimal degradation conditions for GSNO (39).  More alkaline conditions (pH > 9) resulted 
in poor mass spectra with the absence of any recognizable molecular ion.  Three separate single 
ion monitoring scans were performed for GS-NEM, GSNO, and EdAG.  No external EdAG was 
added, thus any EdAG detected was from GSNO degradation to EdAG and S-NO.  Figure 2.3.5 
displays the GSNO degradation after 24 hours, where a substantial amount of GSNO degraded to 
GSH, which was immediately trapped by NEM to form GS-NEM (m/z 433; bottom panel).  A 
very small, insignificant amount of GSNO degraded to EdAG (m/z 274; top panel), which 
demonstrated the inability of GSNO to be a reliable precursor for EdAG chemical synthesis on a 
large scale.  The majority of GSNO remained stable after 24 hours (m/z 337; middle panel). 
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Figure 2.3.5 LC/MS of GSNO 24 hour degradation 
 
 
2.3.3 Identification of EdAG after in vitro Incubation of Busulfan with Human Liver 
Cytosol 
 A mass spectrometric detection method was developed to determine if EdAG is a 
metabolite of busulfan by human liver enzymes.  Busulfan was incubated with GSH and human 
liver cytosol, which contains the major soluble isoforms of GSTs that would normally be present 
in hepatocytes, under physiological conditions of pH 7.4 and 37 °C.  The presence of busulfan 
metabolites was determined by LC/MS analysis after 2 and 24 hours.  Figure 2.3.6 contains 
panels A, B, C, and D that monitored the molecular ions m/z 308, m/z 362, m/z 274, and m/z 581, 
corresponding to reduced GSH, GS+THT, EdAG, and GSG, respectively.  Through two hours of 
41 
 
incubation, busulfan-GSH conjugation catalyzed by GSTs formed the unstable sulfonium 
GS+THT (Panel B) with excess GSH (Panel A) remaining in solution.  The EdAG (Panel C) 
formed, resulting from spontaneous degradation of GS+THT, was immediately conjugated 
through nucleophilic addition by GSH in solution to form the non-reducible thioether (or 
lanthionine) GSG (Panel D). 
 
 
Figure 2.3.6 Busulfan Incubation with Human Liver Cytosol after 2 hours incubation 
 
A 
B 
C 
D 
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Through the next 22 hours, the GSTs continued to conjugate busulfan with GSH to form 
GS+THT, which slowly degraded to EdAG at pH 7.4 and 37 °C.  After 24 hours, the GSH in 
solution was depleted due to enzymatic busulfan conjugation, nonenzymatic conjugation of 
EdAG to form GSG, or oxidation to GSSG (not shown).  Figure 2.3.7 demonstrates the depletion 
of GSH (Panel A), however GS+THT (Panel B) was still abundant because of its slow 
degradation at pH 7.4.  GS+THT degraded much faster at pH 8.4 than under physiological pH 
conditions as shown by previous work in our lab (29).  Due to depletion of GSH and continual 
degradation of GS+THT to EdAG, EdAG (Panel C) was allowed to accumulate as there was little 
or no GSH to trap EdAG to form GSG (Panel D).  EdAG was thus shown to be a busulfan 
metabolite from GST-catalyzed glutathione conjugation. 
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Figure 2.3.7 Busulfan Incubation with Human Liver Cytosol after 24 hours incubation 
 
A 
B 
C 
D 
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DISCUSSION 
 
2.4 
 Mass spectrometry is a powerful analytical tool with the ability to elucidate structural 
information from compounds.  ESI is a soft ionization technique that allows molecules to stay 
intact for analysis of the molecular ion (MH+).  Ion trap mass analyzers have the ability to 
fragment the molecular ion through numerous cycles using multi-stage mass spectrometry (MSn), 
which can help elucidate the structure by studying neutral losses from the MH+ and its product 
ions.  This technology was useful for determining the structure and purity of the synthesized γ-
glutamyldehydroalanylglycine (EdAG) from GSH and CDNB.   
 The first step in the synthesis of EdAG was the formation of the dinitrophenyl-S-
conjugate of glutathione.  This was performed by mixing equimolar solutions of GSH and 1-
chloro-2,4-dinitrobenzene (CDNB) slowly and providing ample time and mixing to ensure 
complete conjugation.  This product was subsequently purified by precipitation from solution 
and recrystallization from hot water.  This reaction is relatively efficient, with product yields 
typically ranging from 54-85%.  Caution must be taken in regards to contact and inhalation of 
CDNB and GS-DNB.  In order to determine whether the bright yellow product was in fact GS-
DNB, ESI-MS/MS was employed to elucidate the structure.  GS-DNB is insoluble in water, thus 
methanol was used to dissolve GS-DNB crystals with 0.1% formic acid.  An intense signal at m/z 
474 appeared, corresponding to the molecular ion (Figure 2.3.1).  Fragmentation of the MH+ was 
performed using CID to study the product ions to ensure validity of the structure.  Because GS-
DNB contains a GSH backbone consisting of glutamate, cysteine, and glycine residues, the 
typical neutral losses by CID associated with GSH were expected, such as the losses of water, 
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glycine, and pyroglutamic acid.  Indeed, fragmentation by CID of GS-DNB showed neutral 
losses of glycine and pyroglutamic acid (Figure 2.3.2).  Pyroglutamic acid is a common neutral 
loss for GSH-containing compounds when analyzed by ESI-MS/MS (40,41).  This suggested that 
the major constituent in the bright yellow product was GS-DNB with a MH+ of m/z 474.  
 From GS-DNB, EdAG was formed by adding strong base (0.5 M NaOH) to facilitate the 
β-elimination of 1-S-(2,4-dinitrobenzene) and leaving the tripeptide γ-
glutamyldehydroalanylglycine, or EdAG.  The bright yellow crystals dissolved in the base 
rapidly and the color of solution quickly turned to a dark amber and eventually to a deep 
orange/brown color over the 30 min stir.  To remove the hydrophobic impurities responsible for 
the dark color, secondary butanol was added to extract the impurities from the aqueous solution 
of EdAG.  The remaining aqueous layer was reduced in volume by approximately 50% by the 
slightly polar nature of sec-butanol and accounting, at least partly, for the poor product yield.  
The dilution of the aqueous layer to 300 mL with deionized water allowed for a more efficient 
ion exchange to occur by the Dowex® H+/Na+ exchange resin, which dropped the pH of the 
solution from 13 to 3.  After evaporation, there was a light brown, water soluble solid.  1H NMR 
and LC/MS/MS confirmed the structure of the major constituent of the product.   
 The 1H NMR showed the presence of the two vinylic protons associated with the 
dehydroalanine moiety of EdAG, suggesting that EdAG was the major product formed.  High 
performance liquid chromatography (HPLC) interfaced with tandem mass spectrometry 
(LC/MS/MS) was then performed to determine the presence of UV-detected impurities with a 
signal in the mass spectrum in the range of m/z 100-1000.  The UV chromatogram showed only 
one major peak at 254 nm, which corresponded to EdAG at m/z 274 as indicated by the unique 
MS/MS fragmentation pattern corresponding to EdAG (Figure. 2.3.4).  The mass spectrum did 
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reveal other impurities present in the aqueous solution of product, particularly the sodium adduct 
of EdAG at m/z 296.  There were other ions present in the mass spectrum, but they were minor 
products compared to EdAG.  It was concluded that EdAG was successfully and sufficiently 
synthesized for use in future experiments.   
 The anticancer agent busulfan is commonly used to treat chronic myelogenous leukemia 
(2,3), polycythemia rubra vera (5), essential thrombocythemia (6), and in high dose therapy, co-
administered with cyclophosphamide, as conditioning therapy prior to hematopoietic or bone 
marrow stem cell transplants (4).  The major route of busulfan metabolism is glutathione 
conjugation catalyzed by GSTA1-1 in the cytosol of hepatocytes (27) to form the unstable 
sulfonium GS+THT as shown in Scheme 1.1.  The sulfonium nonenzymatically degrades to THT 
(26) and the dehydroalanine analog of glutathione, EdAG (29).  As long as GSH is present, 
electrophiles such as EdAG can be conjugated and detoxified.  However during high dose 
busulfan administration, e.g. bone marrow transplant conditioning therapy, GSH can become 
depleted and render the cell vulnerable to reactive electrophiles.  The amount of EdAG produced 
is directly proportional to the amount of metabolized busulfan, however that exact amount is 
nearly impossible to quantitate.  It is assumed that intrahepatocellular concentrations of EdAG 
are not nearly as great as the millimolar concentrations of intracellular GSH.  However the 
increased oxidative stress state of the liver could be associated with depletion of reduced GSH by 
oxidation to GSSG.   
 Busulfan has been shown to deplete intracellular hepatic GSH levels in vitro in murine 
models by as much as 50% (31) and it is known that the major metabolite of the active form of 
the prodrug cyclophosphamide (4-hydroxycyclophosphamide) is detoxified by GSH, further 
depleting GSH.  In myeloablative therapy, busulfan is normally administered first, followed by a 
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washout period of at least 24 hours, then treatment with cyclophosphamide.  Because both drugs 
require GSH for detoxification, it is logical that intracellular hepatic GSH could be reduced to 
levels similar to those of the electrophilic compounds requiring GSH conjugation.  A major 
concern during this combination therapy is the potential onset of hepatic veno-occlusive disease 
(HVOD).  HVOD occurs in zone 3 of the centrilobular region of the liver, which contains the 
highest hepatocyte concentrations of the drug metabolizing enzymes (DMEs) of cytochrome 
P450s and GSTs (42).  As a busulfan metabolite formed from GSTs, EdAG could be 
contributing to HVOD by inhibiting GSTs, or trapping GSH directly, resulting in increased 
busulfan exposure.  EdAG could also be contributing to HVOD by inhibiting GSTs producing 
more circulating busulfan as will be demonstrated in a later chapter.   
 After incubation of busulfan, GSH, and human liver cytosol under physiological 
conditions, EdAG was detected by LC/MS as a busulfan metabolite.  After 2 hours, most EdAG 
formed was immediately trapped by unreacted GSH to form GSG.  This observation is consistent 
with the nonenzymatic and spontaneous conversion of GS+THT to EdAG and supports the 
electrophilic nature of the dehydroalanine-containing EdAG intermediate.  However, after 24 
hours of continuous busulfan conjugation catalyzed by the cytosolic GSTs in human liver 
cytosol, reduced GSH levels became depleted and EdAG was continually being formed by 
spontaneous degradation of GS+THT.  With limited GSH reserves to form GSG, EdAG 
accumulated.  This evidence suggested that EdAG is a busulfan metabolite from in vitro 
metabolism.  Mass spectrometry has been known to form dehydroalanine residues from cysteines 
and serines through CID prior to the ion hitting the mass analyzer (43).  The evidence of the 
accumulation of EdAG after 24 hours incubation suggests that the EdAG detected by LC/MS 
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was not a byproduct of inadvertent mass spectrometric CID, but rather EdAG formation in 
solution by degradation of GS+THT to EdAG and THT.   
 In conclusion, this dissertation work has thus far demonstrated that EdAG can be 
successfully synthesized from a conjugate of glutathione (GS-DNB) and that EdAG is an in vitro 
busulfan metabolite.  The next chapter will study the reactivity of EdAG towards cellular thiols.  
The amino acid L-cysteine, the cysteine-containing tripeptide glutathione (GSH), and protein 
models (bovine insulin and serum albumin) containing reactive cysteine residues will be 
incubated with EdAG to determine the extent of conjugation 
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Chapter 3 
 
Conjugation addition reactions of the 
dehydroalanine analog of GSH toward cellular 
thiols 
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INTRODUCTION 
 
3.1 Reactivity of Dehydroalanines 
3.1.1 EdAG is a dehydroalanine analog of Glutathione 
 Glutathione (GSH) is the most prevalent low molecular weight cellular thiol in 
mammalian cells.  In addition to a major cellular role in oxidative status, there is an important 
function of GSH in sequestering toxic, electrophilic xenobiotics (1).  Nucleophilic reactivity of 
GSH is based on conjugation of its thiol group with electrophilic compounds (2).  Conjugation 
with GSH can either be nonenzymatic nucleophilic addition or catalyzed by the glutathione-S-
transferase (GST) superfamily of enzymes.  There are numerous isoenzymes of GSTs, classified 
into cytosolic (soluble), membrane, or mitochondrial.  There are eight major families of 
mammalian GSTs (alpha, zeta, theta, kappa, mu, pi, sigma, and omega) (3).  Dehydroalanine 
(Dha) residues are formed posttranslationally mostly by a β-elimination of serine and threonine 
residues, but also occurs less readily on cysteine residues.  Dha-containing peptides react as 
Michael acceptors that link cysteine residues with dehydroalanine groups to generate non-
reducible thioethers as a posttranslational modification (4). 
 
3.1.2 Reactivity of Dehydroalanine Moieties within Proteins 
 Dehydroalanine residues are common post-translational modifications within many 
proteins, not just lantibiotics.  In these settings however, the presence of Dha residues are most 
likely a sign of oxidation or damage such that the protein is no longer functional.  For 
dehydroalanines to be formed within proteins, either serine/threonine or cysteine residues must 
be dehydroxylated or dethiolated, respectively.  This occurs most frequently during food 
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processing under the intense heat and alkali conditions that favor the β-elimination of 
cysteine/serine side chains to form the Dha.  Also, an in situ alkaline condition (i.e. nearby basic 
amino acids) can also promote the β-elimination to Dha.  The cysteine-to-Dha transformation has 
been studied in vitro in somatostatin, insulin, and transthyretin (5,6).  When proteins are studied 
by mass spectrometry, the formation of Dha could be caused by instrument itself and essentially 
be artefactual of Dha formation in vivo (7).   
 One common plasma protein that is heavily involved in many physiological processes 
that Dha formation occurs on is human serum albumin (HSA).  HSA is a protein that contains 35 
cysteine residues, 34 of which are involved in disulfide bonds leaving one free cysteine at 
residue position 34.  Human serum albumin has been studied to determine whether the any Cys-
to-Dha transformation is the result of a post-translational modification in vivo, the result of food 
processing, or some other ex vivo factor such as incidental collision-induced dissociation of the 
cysteine thiol side chain in the mass spectrometer.  The existence of the Cys487-to -Dha 
biotransformation on both commercially-purchased HSA and plasma HSA confirmed that the β-
elimination occurred as a post-translational modification in vivo (8).  The presence of a Dha on 
residue position 487 of HSA is indicative of the biotransformation of Cys487-to-Dha and the 
oxidation of the protein, which makes it vulnerable to degradation by proteinases because of the 
changes in secondary and tertiary protein structure (9). 
 Another set of proteins in which dehydroalanine residues are present are human lens 
proteins.  It has been demonstrated that Dha residues exist in many water soluble and insoluble 
human lens proteins (10,11).  The formation of Dha residues originated from either cysteines or 
serines (phosphoserines) that underwent a hydroxide-mediated β-elimination (4,11,12).  Aged 
lens proteins tend to have more Dha residues than younger lens proteins.  When there are nearby 
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cysteines, histidines, or lysines within the same protein or adjacent proteins, lanthionines, 
histidinoalanines, and lysinoalanines form, respectively (13).  The formation of lanthionines are 
favored not because of the presence of more cysteines than histidines or lysines, but the presence 
of glutathione within the human lens (up to 2 mM) (14).  GSH can form disulfide bonds (R-S-S-
R) with existing cysteine residues on proteins or non-reducible thioethers (R-S-R) with Dha 
residues, both of which could result in the aggregation of proteins that lead to cataracts, which 
are more prominent in aged lens proteins because of the incidence of Dha residues (10,15).   
 There are numerous other examples of Dha residues within specific proteins that play a 
role in altering that protein’s function, such as casein, thiostrepton, human plasma mannan-
binding lectin, and histidine ammonia lyase (16-19).  Dehydroalanines have also been 
synthesized within peptides to utilize their reactive properties to study protein interactions or to 
act as inhibitors (4,12,20-31).   
 
3.1.3 Chapter Goals 
 It has previously been demonstrated that EdAG is a busulfan metabolite from an in vitro 
phase II glutathione conjugation reaction catalyzed by soluble GSTs in human liver cytosol.  It is 
desired in this chapter to study the reactivity of the electrophilic EdAG towards cellular 
nucleophiles such as GSH, L-cysteine, and cysteine residues in proteins.  Nucleophilic addition 
of these thiol-containing nucleophiles with the electrophilic EdAG has the potential to form the 
non-reducible lanthionine, or thioether, bridge (R-S-R). 
59 
 
EXPERIMENTAL PROCEDURES 
 
3.2.1 Materials 
 L-Cysteine, formic acid, GSH, and Tris buffer, pH 7.4, tris-(2-carboxyethyl)phosphine 
(TCEP), bovine insulin, bovine serum albumin (BSA), α-cyano-4-hydroxycinnamic acid, and 
trypsin were purchased from Sigma-Aldrich (St. Louis, MO).  Sodium bicarbonate, methanol 
(optima), acetonitrile (optima), isopropyl alcohol, and hydrochloric acid were purchased from 
Fisher Scientific (Pittsburgh, PA).  Pooled human liver cytosol (HLC) from multiple donors, 
containing soluble isoforms of GSTs (20 mg/mL total protein concentration) was purchased from 
BD Gentest (Bedford, MA).  All water used was deionized with a NANOpure® water 
purification system (Barnstead, San Jose, CA).   
 
3.2.2 Instrumentation 
 High-performance liquid chromatography (HPLC) was performed on a Shimadzu 10 Avp 
binary pump HPLC system equipped with a UV/Vis detector (Shimadzu Scientific Instruments, 
Columbia, MD).  Mass spectrometry was performed using an electrospray ionization (ESI) 
quadrupole ion trap (QIT) LCQ DECA (ThermoFisher Scientific, Waltham, MA), capable of 
multi-stage mass spectrometry (MS, MS/MS, MS3).  Matrix-assisted laser desorption ionization-
time of flight (MALDI-TOF) mass spectrometric analyses were performed on a Micromass 
Reflectron MALDI-TOF, (Waters, Milford, MA).   
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3.2.3 EdAG-Cysteine Adduct (S-[β-Alanyl]-glutathione) formed nonenzymatically 
A solution of EdAG in water (1.0 mM) was mixed with a solution of L-cysteine (1.0 mM 
in 100 mM Tris buffer, pH 7.4) in 100 mM Tris buffer, pH 7.4 (final volume, 1.0 ml).  The 
mixture was heated in a 37 °C water bath for 12 hours, with aliquots taken every hour to monitor 
the reaction.  Aliquots were further diluted 200-fold in a solution of 0.1% formic acid in 
methanol/water (50:50, v/v), and the product was detected by electrospray mass spectrometry 
(ESI-MS).  The mass spectrum of the predicted protonated molecular species of m/z 395 was 
consistent with the molecular weight of the cysteine-EdAG conjugate (S-[β-alanyl]-glutathione).  
MS/MS fragmentation of this conjugate was performed under the CID conditions of 30% 
collision energy and 1.5 amu window width.  Further fragmentation of the major MS/MS 
production was subjected to MS/MS/MS (MS3) with a collision energy of 40% and 1.5 amu 
window width. 
 
3.2.4 Conjugate Addition of EdAG with Glutathione 
GSH (1.0 mM in 100 mM Tris buffer, pH 7.4) was mixed with an aqueous solution of 
EdAG (1.0 mM) in 100 mM Tris buffer, pH 7.4, and the mixture was incubated in a 37 °C water 
bath overnight to provide the GSH-EdAG adduct (GSG).  Identification of GSG was structurally 
determined by mass spectral analysis.  The mass spectrum of the predicted component in the 
reaction mixture should give a protonated molecular species ion at m/z 581, consistent with 
molecular mass of the GSH-EdAG (GSG) conjugate.  Tandem MS fragmentation was performed 
on the MH+ ion of GSG in an ion trap mass spectrometer using a collision energy of 30% and a 
1.5 amu window width. 
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3.2.5 EdAG-Glutathione conjugation catalyzed by GSTs 
GSH (1.0 mM in 100 mM Tris buffer, pH 7.4) was mixed with an aqueous solution of 
EdAG (1.0 mM) in 100 mM Tris buffer, pH 7.4, and the mixture was incubated in a 37 °C water 
bath for 12 h in the presence of 0.2 mg of human liver cytosol, which contains all soluble 
isoforms of GSTs.  Identification of GSG was made by LC/MS analysis and a qualitative 
estimate of increased GSG abundance was determined from comparison of controls without 
enzymes versus with enzymes.  Chromatographic separation of the polar compounds was 
achieved using a Thermo Hypercarb column (100 x 2.1 mm I.D., 5 µm particle size) 
(ThermoFisher, Waltham, MA).  A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v, 
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol) 
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9 
minutes, 50→0% B; and from 9-15 minutes, 100% A.  The mass spectrometer was operated in 
the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30 V, 
capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arb. units.  The 
following ions were monitored: m/z 274, m/z 308, and m/z 581, corresponding to EdAG, reduced 
GSH, GSG, respectively.  The signal intensity of GSG formed nonenzymatically was compared 
to that of GSG formed in the presence of GSTs to determine if GSG conjugation was 
significantly enhanced by catalysis by GSTs.   
 
3.2.6 Reactivity of EdAG with Insulin 
 Bovine insulin (MW 5734 Da) consists of an A-chain and a B-chain that is connected by 
two inter-chain disulfide bonds.  The insulin was reduced to the B-chain (MW 3400 Da), 
containing two reactive thiols, by addition of 5 mM tris-(2-carboxyethyl)phosphine (TCEP) to a 
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2 µM solution of bovine insulin in deionized H2O, pH 2.0 (adjusted with 1 M HCl).  The 
reduction to the B-chain was complete within 2 hours and was monitored by both ESI-MS and 
MALDI-TOF.  As a positive control, the B-chain was then incubated with the electrophilic 
Michael acceptor N-ethyl maleimide (NEM; MW 125 amu) to ensure that the two cysteine thiols 
are reactive toward electrophiles with an expected MW of 3650 Da.  Excess NEM (1 mM) was 
used to ensure conjugation to both cysteine residues on reduced B-chain.  Excess EdAG (1 mM) 
was then incubated with unreacted B-chain to determine the extent of EdAG reactivity towards 
cysteine residues on proteins, with an expected product of 3946 Da. 
 
3.2.7 Reactivity of EdAG with Albumin 
 EdAG was reacted with a more biologically-relevant protein, serum albumin, to study the 
reactivity toward the free cysteine residue.  Bovine serum albumin (BSA) was used in lieu of 
human serum albumin due to its availability and alkylation to both NEM and EdAG was 
performed based on a modified method of Li et al (32).  BSA (60 µM), containing 17 disulfide 
bonds, was reduced with 50 mM TCEP and diluted to a volume of 500 µL with 100 mM Tris 
buffer, pH 7.4, for 2.5 hours in a 55 °C water bath.  After cooling, excess NEM or EdAG (400 
mM) was added to reduced BSA for 2 hours, followed by filtration through Microcon 10 kDa 
filters to remove excess TCEP and NEM or EdAG.  Alkylated BSA was reconstituted with 500 
µL of 100 mM NH4HCO3 buffer, pH 8.6 and a 1/20 (trypsin/BSA, w/w) amount of trypsin was 
added to digest the alkylated BSA while incubated overnight in a 37 C water bath.  The digestion 
was quenched by the addition of 20% acetic acid.  The expected BSA peptides from trypsin 
digestion were determined from a protein BLAST search and entered into a spreadsheet.  The 
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peptides containing cysteine residues were added to the mass of either NEM or EdAG to account 
for the expected MW of the modified residue.  Many peptides contained more than one cysteine 
residue.  MALDI-TOF mass spectral analyses were performed by mixing the digest solution with 
a solution of 10 mg/mL α-cyano-4-hydroxycinnamic acid in 0.1% formic acid in 90/10 (v/v) 
ACN/H2O in a 1:1 manner (v/v).  MALDI-TOF analyses were performed in the positive ion 
mode with a full scan range of m/z 500-4000. 
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RESULTS 
 
3.3.1 EdAG-Cysteine Adduct (S-[β-Alanyl]-glutathione) formed nonenzymatically 
 Equimolar amounts of reduced L-cysteine and EdAG were incubated in Tris buffer, pH 
7.4, and monitored by mass spectrometry to determine the extent of conjugation and the structure 
of that adduct.  A molecular ion at m/z 395 was found, which corresponded to the EdAG-
cysteine, or S-(β-alanyl)-glutathione, adduct.  Tandem mass spectrometry was performed on m/z 
395 and the major product ion formed was m/z 266, which corresponds to loss of pyroglutamic 
acid, a typical neutral loss in collision-induced dissociation of glutathione-like compounds 
(Figure 3.3.1).  Minor product ions were formed from m/z 266 using multi-stage MS 
(MS/MS/MS, or MS3) at m/z 248 and m/z 191, corresponding to neutral loss of water and 
glycine, respectively, from the ion at m/z 266.   
 Because EdAG is achiral due to the 1,4-Michael conjugated system containing the 
dehydroalanine moiety, the addition of nucleophiles such as GSH or L-cysteine to EdAG forms a 
new chiral center.  The probability exists that GSG consists of a pair of diastereomers, however 
the stereochemistry of synthesized GSG and S-(β-alanyl)-glutathione was not determined. 
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Figure 3.3.1 MS/MS Fragmentation Pattern of S-(β-Alanyl)-Glutathione 
 
 
3.3.2 Conjugate Addition of EdAG with Glutathione 
 EdAG contains an α,β-unsaturated carbonyl system that adds nucleophiles, such as 
sulfhydryl anions, to form a conjugate or adduct.  Condensation of EdAG with the most 
abundant cellular thiol GSH was performed under physiological conditions and yielded a 
glutathione dimer analog with a non-reducible lanthionine cross-linkage (GSG).  Tandem mass 
spectrometry was performed on the GSG molecular ion m/z 581 to confirm the structure (Figure 
3.3.2), where the product ions formed at m/z 323, m/z 452, and m/z 563 were from neutral losses 
of two pyroglutamic acid molecules, one pyroglutamic acid, and water, respectively.   
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Figure 3.3.2 MS/MS Fragmentation Pattern of GSG 
 
 
3.3.3 EdAG-Glutathione conjugation catalyzed by GSTs 
 To determine if GSG formation was catalyzed by GSTs, the same solution was prepared 
with equimolar amounts of reduced GSH and EdAG along with 0.2 mg of human liver cytosol, 
which contained all soluble forms of GSTs.  Aliquots were taken immediately, and then every 
hour until GSG formation leveled off after 3 hours.  Figure 3.3.3 demonstrates the presence of 
EdAG and GSH at 5 minutes with minor nonenzymatic GSG formation having occurred.  The y-
axes are fixed to the relative abundance of the most intense signal of the three ions.   
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Figure 3.3.3 Nonenzymatic GSG formation after 5 minutes 
 
Figure 3.3.4 demonstrates the changes in the relative abundance of the three ions after 180 
minutes.  GSG is now the most abundant ion present of the three after 3 hours.  GSG formation 
leveled off after 3 hours due to the depletion of reduced GSH, where most was involved in GSG 
formation and the rest oxidized to form GSSG (data not shown). 
EdAG 
GSH 
GSG 
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Figure 3.3.4 Nonenzymatic GSG formation after 180 minutes 
 
 
 In the presence of human liver cytosol, containing soluble isoforms of GST including the 
isoform most responsible for busulfan metabolism to EdAG (GSTA1-1), GSG formation was not 
increased, indicating that EdAG is not a substrate for GSTs as hypothesized.  Figure 3.3.5 
demonstrates the formation of GSG in the presence of GSTs after 180 minutes, with relatively 
less GSG formed than in the absence of GSTs after 3 hours. 
EdAG 
GSH 
GSG 
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Figure 3.3.5 GSG formation in presence of GSTs after 180 minutes 
 
 
3.3.4 Reactivity of EdAG with Insulin 
 The reactivity of EdAG toward thiols was extended to cysteine residues within proteins.  
Insulin is a relatively small protein containing 6 cysteine residues, with 4 on the A-chain and 2 
on the B-chain.  Within the A-chain, 2 cysteines are involved in an intra-chain disulfide bond and 
the other 2 cysteines are each involved in separate inter-chain disulfide bonds with the 2 
cysteines on the B-chain (Figure 3.3.6).   
EdAG 
GSH 
GSG 
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Figure 3.3.6 Bovine Insulin 
 
Electrospray ionization (ESI) and matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometry were both used to study both the multiply-charged ions and 
the singly-charged protein molecular ion, respectively.  MALDI mass spectrometry utilizes a 
pulsed laser to softly ionize (not fragment) the analyte, while offering a higher mass range up to 
8000 Da.  Bovine insulin has a molecular weight of 5734 Da, which provides molecular ions 
(and their charge states) of m/z 1147 (+5), m/z 1434 (+4), and m/z 1911 (+3) in ESI-MS (Figure 
3.3.7).  Intact insulin provides one molecular ion at m/z 5734 when analyzed by MALDI-TOF 
(data not shown).   
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Figure 3.3.7 ESI mass spectrum of intact bovine insulin 
 
 
In order for the cysteine thiols to be reactive, the two inter-chain disulfide bonds must be reduced 
by the reducing agent TCEP.  Figure 3.3.8 depicts the ESI mass spectrum of the B-chain by the 
ions at m/z 850 (+4), m/z 1134 (+3), and m/z 1700 (+2), along with TCEP at m/z 251.  The 
MALDI mass spectrum provides a single molecular ion for the B-chain at m/z 3400 with some 
nonreduced, intact bovine insulin at m/z 5735 (Figure 3.3.9).   
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Figure 3.3.8 ESI mass spectrum of bovine insulin B-chain 
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Figure 3.3.9 MALDI mass spectrum of bovine insulin B-chain 
 
 
 To ensure the B-chain cysteine residues are reactive towards Michael acceptors, NEM 
was incubated with B-chain.  The ESI mass spectrum provides molecular ions at m/z 913 (+4), 
m/z 1217 (+3), and m/z 1825 (+2), which corresponded to the B-chain conjugated to two 
molecules of NEM, along with a TCEP-NEM adduct at m/z 376 (Figure 3.3.10).  The singly-
charged molecular ion of the B-chain+2NEM adduct was demonstrated to be m/z 3650 by 
MALDI-TOF (Figure 3.3.11).   
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Figure 3.3.10 ESI mass spectrum of the B-chain+2NEM adduct 
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Figure 3.3.11 MALDI mass spectrum of the B-chain+2NEM adduct 
 
 
 Finally, EdAG was incubated with unreacted, reduced bovine insulin B-chain in order to 
demonstrate that the electrophilic EdAG can react with thiols of cysteine residues on proteins.  
The MALDI mass spectrum depicts a singly-charged molecular ion at m/z 3946 corresponding to 
the B-chain conjugated to two molecules of EdAG; however most of the B-chain remained 
unreacted at m/z 3400 (Figure 3.3.12).  The multiply-charged molecular ions from ESI were not 
clearly recognized (data not shown). 
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Figure 3.3.12 MALDI mass spectrum of the B-chain+2EdAG adduct 
 
 
3.3.5 Reactivity of EdAG with Albumin 
 The reactivity of EdAG with a cysteine-rich and physiologically-relevant protein, 
albumin, was evaluated.  Human serum albumin is one of the major plasma proteins responsible 
for drug binding that is a marker of oxidative stress (33).  Bovine serum albumin (BSA) was 
used as an albumin model for reactivity toward EdAG.  Several attempts to alkylate the lone free 
cysteine at residue 34 of BSA with EdAG failed under a variety of reaction conditions, possibly 
due to disulfide formation between the free thiols of two BSA molecules.  To activate cysteine 
thiols toward electrophiles, the thiol reducing agent TCEP was added to reduce all 35 cysteine 
residues prior to incubation with excess EdAG or NEM (as positive control).  Table 3.1 provides 
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the relevant trypsin-digested BSA peptides containing cysteine residues that were alkylated by 
EdAG.   
 
Residues Sequence Unmodified NEM-Modified  EdAG-Modified 
581-587 CCAADDK 725.26 975.26 1271.26 
499-507 CCTESLVNR 1024.46 1274.46 1570.46 
460-468 CCTKPESER 1052.45 1302.45 1598.45 
286-297 YICDNQDTISSK 1386.62 1511.62 1659.62 
106-117 ETYGDMADCCEK 1364.48 1614.48 1910.48 
375-386 EYEATLEECCAK 1388.57 1638.57 1934.57 
 
Table 3.1 BSA peptides from trypsin digestion 
 
Due to the abundance of modified peptides, only the most clearly recognizable EdAG-modified 
peptides were presented to demonstrate the reactivity toward cysteine residues of albumin.   
 Figure 3.3.13 depicts the MALDI mass spectra of mass range m/z 1240-1300, where (A) 
is NEM-alkylated BSA and (B) is EdAG-alkylated BSA.  Both spectra contain signals at m/z 
1249 and m/z 1283, which correspond to peptides that do not contain cysteine residues, and thus 
are not modified in either incubation.  Figure 3.3.13 A contains a signal at m/z 1274, which 
corresponds to a 9-residue peptide from positions 499-507, that shows NEM-modified cysteines 
that are unique to the NEM-alkylated BSA (also see Table 3.1).  Figure 3.3.13 B contains a 
signal at m/z 1271, which corresponds to a 7-residue peptide from positions 581-587.  This 
peptide is consistent with two EdAG-modified cysteines.   
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Figure 3.3.13 MALDI mass spectra of mass range m/z 1240-1300 
 
 
A 
B 
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 Figure 3.3.14 depicts the MALDI mass range from m/z 1585-1675, where (A) is the 
NEM-alkylated BSA and (B) is EdAG-alkylated BSA.  Both spectra contain unmodified 
peptides with signals at m/z 1590, m/z 1605, and m/z 1640.  Figure 3.3.14 A contains a unique 
12-residue peptide at m/z 1639 that contains two NEM-modified cysteines corresponding to 
residues 375-386 (see Table 3.1).  Figure 3.3.14 B contains two peptides unique to the EdAG-
alkylated BSA.  The first is a 9-residue peptide from positions 460-468 with two EdAG-modified 
cysteines, corresponding to m/z 1598.  The second is a 12-residue peptide from positions 286-
297 with one EdAG-modified cysteine, corresponding to m/z 1661, although the expected mass 
was 1659 amu.  This 2 mass units difference was accepted because it was unique to the EdAG-
alkylated BSA solution and did not correspond to any unmodified peptides.  It is not known if 
the 2 Da difference represents a dehydrogenation reaction.  
 Figure 3.3.15 depicts the MALDI mass range from m/z 1880-1960, where (A) is the 
NEM-alkylated BSA and (B) is EdAG-alkylated BSA.  Both spectra contain unmodified 
peptides at m/z 1889, m/z 1927, and m/z 1949.  Figure 3.3.15 A contains a unique 16-residue 
peptide from positions 508-523 with one NEM-modified cysteine corresponding to m/z 1948.  
Figure 3.3.15 B contains two modified peptides that are unique to EdAG-alkylated BSA.  The 
first is a 12-residue peptide from positions 106-117 with two EdAG-modified cysteines, 
corresponding to m/z 1911.  The second unique peptide is a 12-residue peptide from positions 
375-386 with two EdAG-modified cysteines, corresponding to m/z 1934.   
 The EdAG-modified peptides of trypsin-digested BSA, as well as bovine insulin, are 
evidence of the formation of lanthionine bridges in proteins in vitro.   
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Figure 3.3.14 MALDI mass spectra of mass range m/z 1585-1675 
 
A 
B 
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Figure 3.3.15 MALDI mass spectra of mass range m/z 1880-1960 
A 
B 
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DISCUSSION 
 
3.4 
 Dehydroalanines occur frequently in nature, such as in albumin, human lens proteins, and 
lantibiotics, as well as chemically during food processing.  These dehydroalanines have been 
shown to be reactive with cellular nucleophiles, most notably GSH, which subsequently forms a 
non-reducible lanthionine bond.   
 The reactivity of dehydroalanines was analogous to the electrophilic dehydroalanine 
analog of glutathione, EdAG, which is a metabolite of the anticancer agent busulfan.  Both the 
amino acid L-cysteine, which contains a nucleophilic side chain thiol, and the most abundant 
form of cellular thiols, the tripeptide glutathione, were reacted with EdAG to determine the 
extent of conjugation that occurs nonenzymatically.  When equimolar amounts of EdAG and 
either L-cysteine or reduced glutathione were incubated in solution under physiological 
conditions of pH 7.4 and 37 °C, conjugation of the thiol to EdAG was detected by mass 
spectrometry.  Tandem mass spectrometry (MS/MS) was used, employing CID to confirm the 
structure of each adduct to ensure the correct conjugate was formed.  These experiments suggest 
that the dehydroalanine moiety in EdAG is sufficiently reactive towards cellular thiols when 
present as the individual amino acid cysteine or the tripeptide GSH.  The non-reducible 
lanthionine bond was formed by nucleophilic addition of a cysteine, either L-cysteine or GSH, to 
a dehydroalanine residue in a tripeptide.  Thus, EdAG could serve as a model peptide-containing 
dehydroalanine to further study lanthionine formation in vivo.   
 Glutathione is a substrate for all GSTs and due to the high intracellular levels of GSH, 
most cytosolic GSTs have GSH constantly bound in the hydrophilic glutathione binding site (G-
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site).  Hydrophobic substrates, such as busulfan, bind to the hydrophobic binding site (H-site), 
which positions the substrate near the reactive thiol of GSH (actually the thiyl GS-) to induce 
conjugation.  EdAG was shown to bind GSTA1-1 on a GSH-agarose gel (34), but that does not 
necessarily imply that EdAG is a ligand of either the G- or H-site.  EdAG and GSH were 
incubated in the presence of GSTs to determine if EdAG could bind the H-site and position itself 
in close proximity to the reactive thiol of GSH in the G-site of GSTs such that GSG formation is 
catalyzed by GSTs.  After 3 hours, the reaction was complete and there was no significant 
increase in GSG formation in the presence of GSTs relative to the nonenzymatic equimolar 
incubation of EdAG and GSH.  This outcome was expected because EdAG is a hydrophilic 
molecule and probably doesn’t bind well or at all in the H-site, thus catalysis for GSG formation 
is less likely.   
 The glutathionylation of proteins is a common post-translational modification (PTM), 
which normally occurs when GSH attacks a cysteine or a dehydroalanine residue on a protein.  
The dehydroalanine residue was originally either a cysteine or a serine that lost the heteroatom 
functional group as a PTM.  It was desired here to determine if EdAG could react with cysteine 
residues on proteins to essentially glutathionylate the proteins, albeit in the reverse order with the 
cysteine residue attacking the dehydroalanine of EdAG.  Insulin was used as a model protein that 
contains two reactive cysteine residues when reduced to its B-chain.  Both electrospray 
ionization (ESI), which produces multiply-charged molecular ions, and matrix-assisted laser 
desorption ionization (MALDI), which produces singly-charged molecular ions, were used to 
study the insulin conjugates with the Michael acceptors N-ethyl maleimide (NEM) and EdAG.  
NEM is a well-known Michael acceptor and was used as a model electrophile to demonstrate the 
ability of Michael acceptors to be conjugated by the reactive cysteine thiols of reduced bovine 
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insulin B-chain.  NEM proved to be an excellent model for Michael acceptors, with mostly all 
the B-chain reacting with NEM.  Because there are two reactive cysteine residues on each B-
chain, there are two NEM molecules added to the B-chain, counting for an additional molecular 
weight of 250 amu.  When incubated in the same molar ratio to B-chain as in the NEM reaction, 
EdAG also reacted with B-chain.  Two EdAG molecules were conjugated per B-chain, 
accounted for by the additional molecular weight of 546 amu.  However, there was mostly 
unreacted B-chain present in the MALDI mass spectrum (Figure 3.3.11), and the B-chain-EdAG 
adduct was a minor product.  This suggests EdAG is a reactive Michael acceptor, but not as 
reactive as NEM.  The evidence that EdAG is a relatively weak Michael acceptor is supported by 
Li et al that suggested electron donation by the enamine functionality weakens the 
electrophilicity of dehydroalanines in comparison with the electrophilicity of more classical 
Michael acceptor compounds (35). 
 In conclusion, the electrophilic dehydroalanine analog of glutathione (EdAG) was shown 
to be reactive towards the cellular nucleophiles L-cysteine, GSH, and cysteine residues on 
bovine insulin B-chain and bovine serum albumin.  This reactivity demonstrated the potential of 
EdAG to trap intracellular GSH with a non-reducible thioether bond that could further deplete 
GSH levels when the anticancer agent busulfan is administered.  Also, EdAG has the potential to 
bind cellular proteins and form non-reducible lanthionines that could alter their function and 
disrupt cellular processes.  One protein of particular interest that EdAG could react with is the 
enzyme responsible for its formation, GSTA1-1.  EdAG was shown to bind GSTA1-1 from 
studies by Younis et al (34), however it was suggested that EdAG is not a substrate of the H-site 
of GSTs, due to the lack of GST-catalyzed GSG formation.  EdAG could however be a substrate 
of the G-site due to its structural similarities to GSH, with the one obvious exception of the lack 
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of the thiol group.  In the next chapter, it was desired to determine the extent of EdAG binding in 
the G-site and if EdAG could act as a competitive inhibitor of GSTs, particularly GSTA1-1 
because it is the most abundant cytosolic GST isoform in the liver and is also the predominant 
isoform responsible for EdAG formation from busulfan. 
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Chapter 4 
 
EdAG-Mediated Inhibition of Glutathione-S 
Transferases 
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INTRODUCTION 
 
4.1.1 Glutathione-S Transferases (GSTs) Superfamily of enzymes 
 GSTs use reduced glutathione (GSH) to adduct electrophilic xenobiotics, such as 
busulfan, to aid in their metabolism and elimination from the body.  There are eight major 
families of mammalian GSTs (alpha, kappa, mu, omega, pi, sigma, theta, and zeta) (1-5), where 
the key residue for GSH activation is a serine for the theta class, but is a tyrosine for all others 
(6,7).  The tyrosine residue is acidic and helps stabilize the bound GSH to allow a basic residue, 
suggested to be Arg15 (8), to activate the GSH by deprotonating the thiol group.  The use of 
Arg15 in forming the thiyl group is exclusive to isoform GSTA1-1.  These interactions lower the 
pKa of the GSH thiol group from 9.0 to a range between 6.9-6.0, allowing the formation of the 
thiyl conjugate (GS) at physiological pH 7.4 and causing a 200-300-fold rate increase in the 
GSH-substrate conjugation (9,10).  The structurally-conserved tyrosine for GST class alpha is 
Tyr-9, class mu is Tyr-6, and class pi is Tyr-7 (6).  GSTs allow glutathione to conjugate 
electrophilic substrates, which in this case is busulfan.  Although busulfan has been shown to be 
metabolized by three of the major cytosolic isoforms of GSTs (alpha, mu, and pi), GSTA1-1 is 
the predominant isoenzyme responsible due to its high abundance in liver (11). 
 
4.1.2 GST A1-1 
 GSTA1-1 is a cytosolic enzyme existing as a homodimer, with each subunit containing 
222 amino acids.  GSTA1-1 has been shown to be the predominant isoenzyme responsible for 
busulfan conjugation and metabolism (11).  In addition to the predominant enzyme for busulfan 
metabolism, GSTA1-1 is also the most abundant isoenzyme found in human liver comprising 
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approximately 3% of soluble proteins in human hepatocytes (2,12).  Each of the two subunits in 
the homodimeric GSTA1-1 contain a catalytic site, consisting of a hydrophilic GSH-binding site 
(G-site), and a hydrophobic substrate-binding site (H-site), where the hydrophobic busulfan 
binds.  GSTA1-1 is known to metabolize a wide variety of different hydrophobic substrates due 
to its substrate promiscuity (13).  The topography of the H-site determines the substrate 
specificity among the various isoenzymes of the cytosolic GST family (14).  There also exists an 
intersubunit solvent-accessible cleft on most GSTs.  On GSTA1-1, the cleft is predominantly 
positively charged and has been shown to have greater affinity towards hydrophilic, multivalent 
negatively charged compounds (15).  Among the substrates believed to bind this cleft are 
bilirubin (16,17) and steroids (18), where both have been shown to noncompetitively inhibit 
through a mechanism involving binding a site other that the catalytic site.   
 EdAG has been previously shown to bind GSTA1-1 (19), although that does not 
necessarily imply that EdAG is a ligand for GSTA1-1 in either of the two binding sites (G-, H-
site).  Previous work in this dissertation has demonstrated that the reaction between EdAG and 
GSH is not catalyzed by GSTs, even though GSH is a substrate of the enzyme.  This indicated 
that EdAG is not a substrate for the hydrophobic substrate binding site (H-site).  Due to the 
structural similarities of EdAG and GSH, it was hypothesized that EdAG could compete with 
GSH for binding in the G-site and competitively inhibit GSTs, namely isoform GSTA1-1. 
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EXPERIMENTAL PROCEDURES 
 
4.2.1 Materials 
 GSH, 1-chloro-2,4-dinitrobenzene (CDNB), α-cyano-4-hydroxycinnamic acid, and Tris 
buffer, pH 7.4, were purchased from Sigma-Aldrich (St. Louis, MO).  All water used was 
deionized with a NANOpure® water purification system (Barnstead, San Jose, CA).  Pooled 
human liver cytosol (HLC) from multiple donors, containing all cytosolic isoforms of GST (20 
mg/mL total protein concentration) was purchased from BD Gentest (Bedford, MA).  Pure 
human recombinant GSTA1-1 (2.5 mg/mL) was purchased from US Biological (Swampscott, 
MA).  Microcon-10 filters (Millipore Corp., Billerica, MA) with a mass cutoff of 10 kDa was 
used to retain GST from solution.   
 
4.2.2 Instrumentation 
 Ultraviolet (UV) absorbance was measured on a Beckman DU 640 UV/Vis 
spectrophotometer (Beckman-Coulter, Fullerton, CA).  Matrix-assisted laser desorption 
ionization-time of flight (MALDI-TOF) mass spectrometric analyses were performed on a 
Micromass Reflectron MALDI-TOF, (Waters, Milford, MA). 
 
4.2.3 Inhibition of GSTs in Human Liver Cytosol by EdAG 
 Inhibition of GST by EdAG was determined using a modified established GST activity 
assay (20) using CDNB, GSH, and human liver cytosol (containing most soluble GST 
isoenzymes) as the catalyst.  CDNB (final conc 1 mM) in methanol (final methanol conc less 
than 0.5%), and GSH (final conc 1 mM) in Tris buffer, pH 7.4 were mixed and diluted with 
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water to a final volume of 2 mL before addition of human liver cytosol (final conc 10 µg 
protein/mL) to start the reaction.  The reaction was monitored over 5 min for the change in 
absorbance at 340 nm.  CDNB concentration was held constant at 1 mM to saturate the H-site, 
while varying concentrations of GSH in the G-site to determine competitive inhibition at the G-
site with EdAG.  Specific activities (or reaction velocities) were calculated as the velocity of 
product S-(2,4-dinitrophenyl)glutathione, or GS-DNB, formed per unit of enzyme over 5 minutes 
using the extinction coefficient of ε = 9.6 mM-1cm-1 (20) in the equation below.   
][
6,9
/
1
340
E
mM
dTdA
v
nm −= , where dA340nm/dt is the change in absorbance at 340 nm over time (5 
minutes), and [E] is the enzyme concentration.  Specific activity is expressed in µmoles/mg/min.  
GSH concentrations were 0.01, 0.05, 0.1, 0.5, and 1.0 mM.  EdAG concentrations were 0, 0.01, 
0.1, 0.5 and 1.0 mM.  Each experiment was performed twice and average velocities were plotted 
by SigmaPlot 8.0 (Systat Software, Inc., Point Richmond, CA) to calculate kinetic parameters. 
 
4.2.4 Inhibition of human GSTA1-1 by EdAG 
 Inhibition of GSTA1-1 by EdAG was determined using the same procedure as above 
with CDNB, GSH, and pure recombinant human GSTA1-1 as the catalyst.  CDNB (final conc 1 
mM) in methanol (final methanol conc less than 0.5%), and GSH (conc ranging 0.01-1.0 mM) in 
Tris buffer, pH 7.4 were mixed and diluted with water to a final volume of 2 mL before addition 
of pure GSTA1-1 (final conc 62.5 ng/mL) to start the reaction.  Specific activities (or reaction 
velocities) were calculated as the velocity of GS-DNB formed per unit of enzyme over 5 minutes 
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using the extinction coefficient of ε = 9.6 mM-1cm-1 (20).  EdAG-induced GSTA1-1 inhibition 
was assayed at the same EdAG concentrations of 0, 0.01, 0.1, 0.5 and 1.0 mM. 
 
4.2.5 Irreversibility of EdAG-mediated inhibition of GSTA1-1 
 Pure GSTA1-1 (1.25 µg) was exposed to varying amounts of EdAG for 30 min at room 
temperature to allow for potential irreversible binding to occur based on a previous study (21).  
The solution was then filtered through a Microcon-10 filter apparatus to remove unreacted 
excess EdAG and retain GSTA1-1.  To condition the filters before use, a pre-wash of 100 µL of 
100 mM Tris buffer, pH 7.4 was performed with the filters centrifuged at 10,000 rpm (13,725 x 
g) for 30 min in an Eppendorf Mini Spin mini-centrifuge (Eppendorf, Westbury, NY).  After the 
30 min incubation and pre-wash, the solution containing GSTA1-1 and EdAG was filtered by 
centrifugation at 10,000 rpm for 45 min.  The enzyme was recovered by reconstitution with 100 
µL of 100 mM Tris buffer followed by a 30 min wash filtration of 100 µL of H2O.  To the 
recovered enzyme in buffer, GSH and CDNB (final concentrations 1 mM) were added and 
diluted with water to a final volume of 2 mL.  The reaction was monitored for 30 minutes to 
assess enzyme activity by monitoring the change in UV absorbance at 340 nm.  Positive controls 
were incubated with 10 mM ethacrynic acid (EA).  Negative controls were incubated without 
EdAG, filtered and reconstituted with substrates, and velocities over 30 minutes were normalized 
to 100% recovered enzyme activity.  EdAG concentrations during pre-incubations were 0.01, 
0.1, 1.0, and 10 mM.  Experiments were performed in triplicate and the average percent 
recoveries calculated.  The means ± standard error of the means (SEM) were plotted and 
significance was determined using a two-tailed, unpaired Student’s t-test, with p < 0.05 as 
statistically significant.   
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4.2.6 Proteomic analysis of the GSTA1-1/EdAG adduct 
 In order for EdAG to form a covalent adduct with GSTA1-1, pure GSTA1-1 (1.8 µM) 
was mixed with 10 mM EdAG for one hour in 10 mM Tris buffer, pH 7.4.  Excess, unreacted 
EdAG was removed by filtration, as described above, and reconstituted in 80 µL of water.  
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometric 
analysis in the positive ion mode was used to determine if GSTA1-1 experienced a mass shift of 
273 Da, equivalent to the mass addition of one EdAG molecule.  A control of unreacted GSTA1-
1 was used to calibrate the MALDI MS signal at 25,730 Da.   
 To elucidate the potential residue of GSTA1-1 that is conjugated to EdAG, a trypsin 
digestion was performed.  Again, 1.8 µM GSTA1-1 was incubated with 10 mM EdAG for one 
hour in 10 mM Tris buffer, pH 7.4, followed by filtration to remove excess unreacted EdAG.  
The GSTA1-1 was reconstituted from the filters with 80 µL of 100 mM ammonium bicarbonate 
buffer, pH 8.6 in order to optimize enzyme conditions for the trypsin digest.  A 1 mg/mL 
solution of trypsin was made in deionized water adjusted to pH 3.0 with 10 mM HCl.  A 1/20 
(w/w) addition of trypsin/GSTA1-1 was made to the reconstituted GSTA1-1 in 100 mM 
NH4HCO3 and incubated in a 37 °C water bath overnight for 18 hours.  The samples were mixed 
with α-cyano-4-hydroxycinnamic acid as matrix (1:1, v:v), spotted and dried on MALDI plate 
prior to analysis by a Micromass Reflectron MALDI-TOF mass spectrometer in the positive ion 
mode.  A protein BLAST search was performed to list expected peptides from tryptic digestion.  
The peptide containing the cysteine residue will be monitored in control and with EdAG to 
detect any modifications of that cysteine by EdAG. 
98 
 
RESULTS 
 
4.3.1 Inhibition of GSTs in Human Liver Cytosol by EdAG 
 The inhibitory effects of EdAG were first evaluated using soluble GST isoforms in 
human liver cytosol by varying GSH and EdAG concentrations over a 100-fold range.  The data 
are consistent with enzyme inhibition or inactivation involving mechanisms other than simple 
competitive processes.  Figure 4.3.1 displays the Michaelis-Menton plot that suggests either 
irreversible or noncompetitive inhibition.  Human liver cytosol provided an in vitro model of in 
vivo GST activity in liver. 
 
 
Figure 4.3.1 GST inhibition by EdAG 
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4.3.2 Inhibition of GSTA1-1 by EdAG 
 To determine the effect of EdAG on the major isoform of GST associated with EdAG 
formation, inhibition studies with pure recombinant human GSTA1-1 were performed.  Under 
the same incubation conditions as for the cytosolic fraction experiments, recombinant human 
GSTA1-1 was inhibited by EdAG in a manner that suggested either irreversible or 
noncompetitive inhibition.  The mechanism of inhibition as noncompetitive is in accordance with 
the previous experiment involving all cytosolic isoforms of GSTs in human liver cytosol.  The 
apparent KM and apparent VMAX for the reaction shown in Table 4.1 provide a calculated IC50 
value of 99.2 µM for inhibition of GSTA1-1 by EdAG.   
 
[EdAG] (mM) 0 0.01 0.1 0.5 1 
 
KMapp  (µM) 85.8 131 177 67.8 79.7 
VMAXapp 
(µmoles/mg/min) 
40.1 40.8 19.1 6.21 6.34 
 
Table 4.1 Enzyme Kinetic Parameters for GSTA1-1 Inhibition by EdAG Support Mixed 
Noncompetitive Inhibition 
 
The results were not consistent with competitive inhibition at the G-site.  The data were better 
explained by a complex inhibitory mechanism, as likely to be expected for a two-substrate 
enzyme, such as GST.  The data support mixed noncompetitive inhibition based on unequal 
values given for both KIC (523 µM) and KIU (252 µM), respectively representing binding 
constants for competitive and uncompetitive inhibitors (22).  The Michaelis-Menton plot is 
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pictured in Figure 4.3.2 that suggests either irreversible or noncompetitive inhibition of GSTA1-
1 by EdAG. 
 
 
Figure 4.3.2 GSTA1-1 inhibition by EdAG 
 
To further suggest noncompetitive inhibition, other kinetic diagrams were plotted such as 
Lineweaver-Burk (Figure 4.3.3), and Hanes-Woolf (Figure 4.3.4) plots, that both suggested 
noncompetitive inhibition based on the estimated extrapolated intersection point of the lines in 
the negative x-axis and the unparallel lines.  The slopes of both plots are equivalent to the inverse 
of VMAX, and because VMAX is changing, so are the slopes. 
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Figure 4.3.3 Lineweaver-Burke plot suggests noncompetitive inhibition of GSTA1-1 by EdAG 
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Figure 4.3.4 Hanes-Woolf plot suggests noncompetitive inhibition of GSTA1-1 by EdAG 
 
 
 To determine if there is a preference for inhibition at the G- or H-site of GSTA1-1, the 
enzyme assay was repeated holding GSH concentration constant at saturating levels (1.0 mM) 
and varying concentrations of CDNB.  Concentrations of EdAG near the IC50 of 99.2 µM 
displayed negligible decreases in velocity, suggesting that EdAG binding was not occurring at 
the H-site (Figure 4.3.5).  The decrease in velocity when EdAG was 1 mM results from the same 
GST inhibition observed in Figure 4.3.2, when all substrates and inhibitor were 1 mM.  This 
experiment strongly suggested that EdAG is binding a separate non-substrate binding, or 
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ligandin, site that is neither the G-site where GSH binds nor the H-site where CDNB and other 
hydrophobic xenobiotics bind.   
 
Figure 4.3.5 EdAG not inhibiting at substrate binding site 
 
 
4.3.3 Irreversible Inhibition of GST by EdAG 
 The potential for irreversible inhibition of GST by EdAG was evaluated.  The Michaelis-
Menton kinetic profiles of noncompetitive and irreversible inhibitors are similar in that inhibition 
is concentration-dependent and enzyme activity cannot be restored by increasing substrate 
(GSH) concentration.  To determine if EdAG is also an irreversible inhibitor, EdAG was 
incubated at room temperature with GSTA1-1 in the absence of substrates to allow for 
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irreversible binding to occur.  Figure 4.3.6 shows that a 30-minute preincubation of EdAG at 10 
mM concentration with GSTA1-1 in the absence of GSH and CDNB showed irreversible 
inhibition.  Inhibition by preincubation concentrations at or below 1 mM EdAG was not 
observed after 30 minutes.  As a control for irreversible inhibition, preincubation of GSTA1-1 
with ethacrynic acid (10 mM) inactivated the enzyme irreversibly (23).  Experiments were 
conducted that demonstrated the binding reaction was complete after 30 minutes and no further 
inhibition occurred with preincubation times up to 2 hours (data not shown).  Preincubations in a 
37 °C water bath compared to at room temperature also did not affect binding efficiency.  Each 
bar is the average percent recovered GSTA1-1 activity (n=3) ± SEM.  A two-tailed, unpaired 
Student’s t-test was used to calculate significant difference in % activity (* P value <0.05 for 
reactions containing 10 mM EA versus 0.01-1 mM EdAG was considered statistically 
significant). 
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Figure 4.3.6 Irreversible inhibition of GSTA1-1 by EdAG and ethacrynic acid 
 
 Further experiments were performed to determine whether EdAG was covalently binding 
GSTA1-1.  GSTA1-1 is a homodimer, with each subunit containing a cysteine residue at position 
112.  The most likely alkylation site is at a cysteine residue of GST.  In the native homodimer, 
the two cysteines are located in the solvent-accessible cleft that forms between the two 
monomers.  Figure 4.3.7 depicts the native conformation of the GSTA1-1 homodimer with the 
two cysteine residues (highlighted in green) courtesy of molecular modeling of the known crystal 
structure by John Jett.  The position of these cysteine residues in the solvent cleft could 
determine the mechanism of GSTA1-1 irreversible inhibition by 10 mM EdAG.  It was shown in 
Chapter 4 that EdAG is noncompetitively inhibiting GSTA1-1 at lower concentrations (≤ 1 mM) 
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at a site other than the catalytic sites (G-, H-site), and literature has demonstrated compounds 
that noncompetitively inhibit by binding at the solvent cleft (16,17).   
 
4.3.4 Proteomic analysis of the GSTA1-1/EdAG adduct 
 The irreversible inhibition of GSTA1-1 by 10 mM EdAG was further characterized to 
determine if EdAG, an electrophilic compound previously shown to be conjugated by cysteine 
residues in insulin and albumin, is being conjugated by one or both of the cysteine residues in the 
solvent cleft.  GSTA1-1 was preincubated with 10 mM EdAG for up to one hour before removal 
of excess EdAG and reconstitution of GSTA1-1 in water for analysis by MALDI looking for an 
intact total mass shift corresponding to EdAG adduction. 
 
Figure 4.3.7 GSTA1-1 contains two cysteine residues in the solvent cleft 
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Compared to control GSTA1-1, no mass shift was detected by MALDI for incubations of 
GSTA1-1 with ≤ 1 mM EdAG, which was expected.  However, at 10 mM EdAG, a mass shift of 
400+ Da was detected.  The exact implications of this shift were not entirely clear, yet it 
corresponds with Figure 4.3.6 that only the 10 mM EdAG incubation irreversibly inhibited 
GSTA1-1.   
 To more fully characterize a potential alkylation of EdAG by GSTA1-1, a trypsin 
digestion was performed prior to analysis by a Micromass Reflectron MALDI-TOF.  Roughly 60 
% of the expected tryptic peptides of GSTA1-1 were detected, but not the peptide containing the 
cysteine residue at position 112.  Thus, it was not possible to elucidate whether EdAG was 
covalently adducted to Cys112.  In the sample containing 10 mM EdAG, the same GSTA1-1 
tryptic peptides were detected as in control, indicating that EdAG was not conjugated to any 
other residues. 
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DISCUSSION 
 
4.4 
 The metabolism of the chemotherapeutic agent busulfan results in the formation of a 
dehydroalanine analog of glutathione (EdAG) that contains an α,β-unsaturated system and 
renders the molecule an electrophilic Michael acceptor.  Although dehydroalanines are relatively 
weak Michael acceptors because enamine intermediates contribute electron density to the 
electrophilic site (24), EdAG does react with the Michael donors GSH and cysteine, forming a 
thioether or lanthionine bond (19), as well as cysteine residues on insulin B-chain and serum 
albumin, previously demonstrated in Chapter 3 of this dissertation.  The reactivity of EdAG 
toward proteins was extended to GSTs, which were previously indicated to bind GSTs and the 
mechanism of inhibition from binding of EdAG was characterized. 
 GST transfers glutathione to electrophilic substrates by a ternary complex mechanism 
(25).  EdAG is an electrophilic compound that has been shown to bind GSTA1-1 (19).  EdAG is 
not a substrate for GST, yet acts as a GST inhibitor.  When incubated with human liver cytosolic 
fraction or pure recombinant human GSTA1-1, micromolar concentrations of EdAG 
demonstrated mixed noncompetitive inhibition, with a predominantly uncompetitive mechanism 
due to the value of KIU being lower than KIC as calculated by SigmaPlot.  The apparent VMAX 
decreased substantially in the presence of increasing concentrations of EdAG, while the apparent 
KM values varied relatively less (Table 4.1), further indicating noncompetitive inhibition.  Mixed 
noncompetitive inhibition was suggested based on the observation of changes in both the 
apparent VMAX and apparent KM.  If only apparent KM changes, the mechanism is considered 
simple competitive inhibition, and if only apparent VMAX changes, its pure noncompetitive.  
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When both apparent VMAX and KM values change, it is considered mixed-type inhibition, and 
because apparent VMAX values changed significantly more than apparent KM, the term mixed 
noncompetitive inhibition was appropriate.  Furthermore, when the values calculated for KIC and 
KIU (binding constants of competitive and uncompetitive inhibitors, respectively) are both 
calculated by SigmaPlot and are equal, the reaction is classified as pure noncompetitive (22).  
Since KIC was calculated to be greater than KIU, EdAG exhibited predominantly uncompetitive 
inhibition, which in this instance indicated that EdAG was binding at a non-catalytic binding site, 
or ligandin site.   
 One explanation for the mixed noncompetitive inhibition is the suggested participation of 
a separate inhibitor binding site of higher affinity for EdAG than that of the G-site or H-site.  The 
solvent cleft formed between the two subunits of the homodimeric GSTA1-1 could serve as the 
non-catalytic binding site for EdAG, which is supported by literature (16-18,26).  From these 
experiments, it is not clear whether multiple binding sites and multiple substrates are 
participating in the overall reaction.  Another explanation of the complex mechanism of  
GSTA1-1 inhibition by EdAG was irreversible binding.  Michaelis-Menton plots of 
noncompetitive and irreversible inhibition look similar.  Noncompetitive inhibition was initially 
proposed due to the Lineweaver-Burk and Hanes-Woolf plots that both suggested mixed 
noncompetitive inhibition by the changing slopes and the location of the intersection of the best-
fit lines in the negative x-axis.  Irreversibility experiments were performed nonetheless to rule it 
out and further support the mixed noncompetitive inhibition mechanism at concentrations at or 
less than 1 mM EdAG. 
 GSTA1-1 was preincubated with various concentrations of EdAG (1000-fold 
concentration range) for 30 minutes, which is ample time for covalent or irreversible binding to 
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occur.  At micromolar EdAG concentrations, GSTA1-1 was not irreversibly inhibited, although 
minimal irreversible inhibition occurred (10-20%), which could also be attributed to less enzyme 
protein recovery.  At higher concentrations than expected for physiological conditions, 
millimolar concentrations of EdAG (10 mM) irreversibly inactivated GSTA1-1, presumably 
through covalent bond formation.  EdAG concentrations of 1 mM showed more irreversible 
inhibition than micromolar concentrations, but not to the same extent as the 10 mM EdAG or the 
10 mM ethacrynic acid positive control, a known irreversible inhibitor of GSTs (23).  The EdAG 
concentration of 10 mM irreversibly inhibited GSTA1-1 to the same extent as the ethacrynic acid 
control.  This suggested that at lower concentrations, EdAG demonstrates reversible mixed 
noncompetitive inhibition and at concentrations at or above 10 mM, EdAG demonstrates 
irreversible inhibition. 
 EdAG is a reactive electrophile previously shown in this dissertation to be conjugated by 
cysteine residues on proteins such as insulin B-chain and serum albumin.  GSTA1-1 is 
irreversibly inactivated by high concentrations of EdAG and is suggested to be covalently bound.  
Because cysteine residues are the most nucleophilic, thus most likely, residue to conjugate 
EdAG, it was hypothesized that EdAG was bound to a cysteine residue in GSTA1-1.  The 
GSTA1-1 homodimer contains only two cysteine residues out of a total of 444 residues, with one 
on each subunit at position 112.  The published crystal structure of GSTA1-1 was modeled and 
showed that the two cysteine residues reside in the solvent cleft (Figure 4.3.7), where EdAG is 
suggested to interact with GSTA1-1.  High mass MALDI mass spectrometry was performed and 
detected a mass shift in the intact GSTA1-1 when incubated with 10 mM EdAG.  Incubations 
with less than 10 mM did not register a mass shift for GSTA1-1 by MALDI.  When digested 
with trypsin, the peptide containing the cysteine residue was not detected by a Reflectron 
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MALDI-TOF, thus it could not be concluded whether EdAG was covalently bound to Cys112.  
An alternative hypothesis for the reversible inhibition at lower EdAG concentrations and 
irreversibly at 10 mM EdAG is that EdAG is binding tightly but not covalently.  Thus, at high 
concentrations (nonphysiological), the noncovalent interactions are strong enough to irreversibly 
inhibit GSTA1-1. 
 It is known that when GSH is not bound in the G-site, located in the C-terminal domain 
of GSTA1-1, the native homodimer is suggested to assume numerous conformations (27-29), 
although this has not been demonstrated through crystal structures.  The propensity of GSH to 
bind in the G-site ultimately drives GSTA1-1 to assume its normal homodimeric native 
conformation that has been crystallized.  When substrates are not bound, the C-terminal domain 
in the apo GSTA1-1, which is mostly α-helical, can shift such that the G-site is more accessible 
to GSH (30).  The C-terminal can ultimately denature, however the favored binding of GSH can 
slow the denaturing of the overall quaternary structure by stabilizing the C-terminal α-helix 
(6,31).  When a ligandin, or non-substrate, is bound in the solvent cleft, this can alter the C-
terminal domain that governs access to GSH binding to the G-site (6).  If EdAG is 
noncovalently, but tightly binding in the solvent cleft, this could be preventing GSH from 
binding the G-site, thus causing irreversible inhibition of GSTA1-1. 
 In conclusion, it was demonstrated in this chapter that the electrophilic dehydroalanine 
analog of glutathione, EdAG, induces a concentration-dependent inhibition of GSTA1-1 activity.  
At concentrations at or below 1 mM, the mechanism is reversible mixed noncompetitive, but 
above 1 mM, EdAG irreversibly inactivates GSTA1-1.  Since EdAG inhibits GST-mediated 
busulfan metabolism and is a metabolite of the GSH adduct of busulfan, it is suggested that 
product inhibition kinetics could influence busulfan pharmacokinetics.  With a calculated IC50 of 
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99.2 µM of EdAG for GSTA1-1, physiological concentrations of EdAG could induce GST 
inhibition and prolong the presence of busulfan in the liver, potentially causing hepatotoxicity. 
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Chapter 5 
Reactivity of EdAG as a Radical Scavenger 
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INTRODUCTION 
5.1.1 Dehydroalanines as free radical scavengers 
 N-Acylated dehydroalanines, of which EdAG is an example, have radical scavenging 
properties through a captodative mechanism (1).  This unusual class of reactive oxygen species 
(ROS) scavengers involves carbon-based radical intermediates that differentiate captodative 
mechanisms from the scavenging properties of GSH, N-acetylcysteine, and ascorbic acid (2).  
GSH is the most abundant cellular thiol and plays a major role in ROS scavenging, as well as in 
transition metal transport due to the ability of the thiol moiety to donate a hydrogen atom with an 
electron pair (Figure 5.1.1).  
 
Figure 5.1.1 Glutathione redox mechanism for radicals 
 
Amino acids and peptides that undergo a one-electron oxidation are examples of captodative 
stabilization of carbon-based radicals (3).  The structural features that stabilize a captodative 
radical on the α-carbon of a peptide are adjacent groups consisting of a lone pair-donating amide 
nitrogen and an electron-withdrawing carbonyl.  Captodative free radical intermediates have 
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been identified in the addition of hydroxyl radical to dehydroalanine compounds (4) as 
demonstrated in Figure 5.1.2.   
 
Figure 5.1.2 Captodative mechanism of radical scavenging by dehydroalanines 
 
 Dehydroalanine-containing compounds constitute an unusual class of radical scavengers 
that have been studied for the past few decades and the proposed mechanisms are different from 
redox mechanisms utilized by the more common reducing agents GSH, N-acetyl cysteine, and 
ascorbic acid.  N-acyldehydroalanines contain both electron-withdrawing and electron-donating 
groups that form a captodative substitution system (5), which surrounds a central alpha carbon in 
a dehydroalanine amino acid residue.  The carbonyl system serves as the electron-withdrawing 
group, allowing the β carbon adjacent to the central α carbon to obtain a partial positive charge 
and make an electrophilic site for attack by ●OH.  The resulting free electron is then stabilized on 
the α-carbon by captodative mechanisms, where the amide group adjacent to the α carbon is the 
electron-donating group and the carbonyl group adjacent to the α carbon is the electron-
withdrawing group (Figure 5.1.2).  The stabilized radical does not polymerize, but rather 
dimerizes with other stabilized radicals (6).  There are numerous examples of low molecular 
weight compounds containing dehydroalanine moieties that are able to scavenge ROS such as 
hydroxyl (●OH) and superoxide (O2-●) radical, as well as reducing lipid peroxidation  (1,4,7-13).  
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Acyldehydroalanines reduce the amount of hydroxyl radical formed in the Fenton reaction, 
suggesting that these compounds could be successful as ROS scavengers in biological systems.  
Suzen et al synthesized eleven N-acyl dehydroalanine compounds to study their free radical 
scavenging properties by testing the protection against lipid peroxidation as well as scavenging 
of 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical, where the dehydroalanine compounds 
protected against peroxidation but did not scavenge DPPH radical due to the lack of a redox thiol 
functional group as expected (12).   
 
 In this chapter, the dehydroalanine analog of glutathione, EdAG, was tested using the 
previously mentioned reactions (DPPH, Fenton reaction and EPR) to study carbon-based radical 
formation through hydroxyl radical trapping.  Mass spectrometry was added to structurally 
identify the EdAG-hydroxyl radical adduct.   
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EXPERIMENTAL PROCEDURES 
5.2.1 Materials 
 GSH, Tris buffer, pH 7.4, 5,5-dimethyl-1-pyrroline-N-oxide (DMPO), α-(4-pyridyl N-
oxide)-N-tert-butylnitrone (POBN), 1,1-diphenyl-2-picrylhydrazyl (DPPH), N-acetylcysteine 
(NAC), Tris buffer, pH 7.4, PBS, serum free media (SFM), Dulbecco’s modified eagle’s medium 
(DMEM), fetal bovine serum (FBS), hydrogen peroxide (H2O2), sodium dichromate,  xanthine, 
xanthine oxidase, and ferrous sulfate (FeSO4) were purchased from Sigma-Aldrich (St. Louis, 
MO).  All water used was deionized with a NANOpure® water purification system (Barnstead, 
San Jose, CA).  RAW 264.7 mouse monocyte macrophages and BEAS-2B bronchial epithelial 
cells were purchased from American Type Culture Collection (ATCC, Rockville, MD).  The spin 
trap DMPO was purified by charcoal decolorization and vacuum distillation to remove any 
electron spin resonance (EPR)-detectable impurities. 
 
5.2.2 Instrumentation 
 Ultraviolet (UV) absorbance was measured on a Beckman DU 640 UV/Vis 
spectrophotometer (Beckman-Coulter, Fullerton, CA).  Electron paramagnetic resonance (EPR) 
(or electron spin resonance, EPR) was performed on a Bruker EMX spectrometer (Bruker 
Instruments, Billerica, MA) with a flat-cell assembly.  High-performance liquid chromatography 
(HPLC) was performed on a Shimadzu 10 Avp binary pump HPLC system equipped with a 
UV/Vis detector (Shimadzu Scientific Instruments, Columbia, MD).  Mass spectrometry was 
performed using an electrospray ionization (ESI) quadrupole ion trap (QIT) LCQ DECA 
(ThermoFisher Scientific, Waltham, MA), capable of multi-stage mass spectrometry (MS, 
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MS/MS, MS3).  Accurate mass analysis was performed on an ESI LTQ-FT (ThermoFisher, 
Waltham, MA).   
 
5.2.3 Reactivity of DPPH radical with GSH and EdAG 
 The stable free radical DPPH? in methanol (final conc. 250 µM) was mixed with varying 
concentrations of GSH, N-acetylcysteine (NAC), or EdAG (final methanol conc. was 50%) 
based on literature procedures using DPPH (12).  A control DPPH? solution in 1 mM Tris buffer, 
pH 7.4 was used to determine baseline changes in absorbance at 515 nm over 30 minutes.  
Concentrations of GSH, NAC, and EdAG ranged from 0-500 µM.  Reduction of DPPH? to 
reduced DPPH was calculated using the extinction coefficient for DPPH? at 515 nm, 1.16x104 M-
1 cm-1 (2).  Experiments were performed in duplicate and averaged to determine velocity of 
DPPH? to reduced DPPH. 
 
5.2.4 Formation of the EdAG Captodative Radical In Vitro 
 Hydroxyl radical scavenging activity by EdAG was monitored by electron paramagnetic 
resonance (EPR) experiments conducted on a Bruker EMX spectrometer (Billerica, MA).  
Hydroxyl radical (●OH) was generated by the Fenton reaction containing H2O2 (0.1 mM) and 
FeSO4 (0.1 mM).  The reaction mixture also contained either DMPO (100 mM) or POBN (20 
mM) as spin traps, and the captodative radical scavenger EdAG (0-50 mM) in a final volume of 
300 µL containing PBS, pH 7.4.  H2O2 was added last to initiate the formation of ●OH before the 
reaction was immediately transferred to a flat-cell for EPR analysis.  As the short-lived hydroxyl 
radical is formed, it is immediately trapped by DMPO or POBN to obtain the DMPO-OH● or 
POBN-OH● spin adduct, respectively, that is observed as a spin-trapped signal in the EPR.  Note 
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that only one spin trap (DMPO or POBN) is used in a run.  Presence of other ●OH-scavenging 
compounds will decrease that signal through competition for hydroxyl radical, and a rate 
constant of scavenging for EdAG (kE) can be calculated compared to that of DMPO (kD) as 
described previously (14,15).  Experiments were performed under ambient air at room 
temperature in triplicate, and the average values used to determine the rate of scavenging for 
EdAG (kE) from the equation:  
V/v -1 = kE[EdAG]/kD[DMPO], where V and v are the velocities of ●OH scavenging in the 
presence and absence of EdAG, respectively, and kE and kD represent the rate constant for 
hydroxyl radical scavenging by EdAG and DMPO, respectively.  The literature value used for kD 
was 2.1 x 10-9 M-1s-1 (16).  POBN was used as a supplemental spin trap to draw further 
conclusions as to the mechanism of EdAG-hydroxyl radical scavenging, and not for rates of 
scavenging calculations.  The mean ± SEM were plotted for each concentration of EdAG and a 
two-tailed, unpaired Student’s t-test was employed to determine statistical differences. 
* Significance was determined with a p < 0.05.   
 The scavenging ability of EdAG was qualitatively assessed against the superoxide radical 
(O2-?).  Superoxide was generated by the xanthine [3.5 mM] and xanthine oxidase [2.0 U/ml] 
system.  A single concentration of EdAG (20 mM) was mixed with xanthine and xanthine 
oxidase and immediately transferred to a flat cell for EPR analysis.  
 
5.2.5 Mass spectrometric identification of EdAG-hydroxyl radical adduct 
 A Fenton reaction using 2 mM of both H2O2 and FeSO4 with either 5 or 10 mM EdAG 
was performed in a test tube and immediately analyzed by LC/MS.  Controls of EdAG with only 
Fe2SO4 and EdAG with only H2O2 were run to ensure the desired product is strictly formed from 
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the reaction of EdAG with hydroxyl radical formed by the Fenton reaction.  HPLC conditions 
performed on a Shimadzu 10 AVP (Shimadzu Scientific, Columbia, MD) following an injection 
volume of 10 µL were as follows: A Thermo Hybercarb column (100 x 2.1 mm, 5 µm, 
ThermoFisher, Waltham, MA) was used to isolate the product from other constituents in the 
reaction mixture.  A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v, 
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol) 
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9 
minutes, 50→0% B; and from 9-15 minutes, 100% A.  The LCQ DECA mass spectrometer was 
operated in the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30 
V, capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arbitrary units.  
Tandem mass spectrometry (MS/MS) was performed on the major product in the reaction 
mixture (m/z 581.2) with an isolation width of 1.0 amu and a percent collision energy of 30% on 
the LCQ DECA ion trap mass spectrometer.   
 
5.2.6 Accurate mass analysis of the ESG dimer 
 Accurate mass calculations of the EdAG-OH (the serine analog of GSH, or ESG) dimer 
were performed on a LTQ-FT mass spectrometer (ThermoFisher, Waltham, MA) in the Fourier 
transfer (FT) mode.  The LTQ-FT calculated a theoretical mass from the chemical formula 
C20H33N6O14, consistent with protonated ESG dimer.  The Fenton reaction consisting of 2 mM of 
both H2O2 and FeSO4 was mixed with 10 mM EdAG to produce the ESG dimer and directly 
injected into the LTQ-FT mass spectrometer for accurate mass analysis.  The observed accurate 
mass obtained and its accuracy compared to the theoretical accurate mass was calculated.  Mass 
differences of 5 ppm or less from the theoretical mass are considered to be accurate.  Tandem 
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MS was performed in the FT mode on the LTQ-FT to obtain accurate mass calculations of the 
MS/MS fragment ions of the ESG dimer.  The parent ion m/z 581.20 was fragmented with a 
collision-induced dissociation (CID) energy setting of 35. 
 
5.2.7 Reaction of EdAG with Hydroxyl Radical (●OH) in RAW 264.7 Cells 
 RAW 264.7 cells (3x106/well) were cultured in DMEM over 24 hours in a 37 °C 
incubator.  The cells were then incubated with varying concentrations of EdAG for a period of 1 
hour in a 37 °C incubator.  After 1 hour, the cells were transferred to a mini centrifuge tube, 
followed by the addition of potassium tetraperoxochromate (source of Cr[VI]) and DMPO to 
induce ROS production (specifically ?OH) and trap radicals for detection in EPR, respectively.  
The solution was mixed and quickly transferred to a flat cell for EPR analysis.   
 
5.2.8 EdAG Cell Permeability 
 Six wells of 500,000 BEAS-2B (bronchial epithelial cells) were plated overnight in a 37 
°C incubator in DMEM growth serum.  Solutions of EdAG in PBS (100, 200, and 500 µM) were 
aliquoted and 2 mL added to cells after 2 mL of fetal serum albumin (FBS) growth media was 
removed.  EdAG was incubated with cells for 1 hour at 37 °C.  Afterwards, 1 mL of media was 
removed and transferred to a mini-centrifuge tube and centrifuged at 13,000 rpm for 15 minutes 
at 4 °C.  The supernatant, which contained EdAG that did not enter cell, was analyzed by LC/MS 
to quantify EdAG.  The remaining media was removed from each well and replaced with 500 µL 
of either deionized water (to 3 wells containing each EdAG concentration) or 0.05% digitonin (to 
other 3 wells) in order to lyse the cells.  Cells were immediately scraped to detach them from the 
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plate and the 500 µL media was transferred to a mini-centrifuge tube where it sat for 30 minutes 
at room temperature to lyse the cell.  After 30 minutes, tubes were centrifuged at 13,000 rpm for 
15 minutes at 4 °C to removed cell fractions and obtain cytosol as supernatant.  Samples were 
then analyzed by LC/MS to quantify EdAG in cytosol of cells.  Chromatographic separation was 
achieved using a Thermo Hypercarb column (100 x 2.1 mm I.D., 5µm particle size) 
(ThermoFisher, Waltham, MA).  A gradient of mobile phase A (0.5 % formic acid in 90/10, v/v, 
water/acetonitrile) and mobile phase B (0.1 % formic acid in 50/50, v/v, isopropanol/methanol) 
at 0.2 mL/min was run from 0-5 minutes using 100% A; from 5-7 minutes, 0→50% B; from 7-9 
minutes, 50→0% B; and from 9-15 minutes, 100% A.  The LCQ DECA mass spectrometer was 
operated in the positive ion full scan mode with a spray voltage of 5.2 kV, capillary voltage of 30 
V, capillary temperature of 300 ºC, and a nitrogen sheath gas flow rate of 80 arb. units.  The 
following ions were monitored: m/z 274, and m/z 308, corresponding to EdAG and GSH.  GSH 
was monitored to determine if cells were effectively lysed.  The presence of GSH in cell lysates 
after addition of digitonin confirmed the lysing of the cells. 
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RESULTS 
5.3.1 Comparison of the reactivity of GSH, N-Acetylcysteine and EdAG with DPPH 
radical 
 In comparison to Suzen et al that demonstrated the inability of dehydroalanine-containing 
compounds to scavenge DPPH radical (DPPH●) (12), EdAG was mixed with DPPH● to 
determine its redox capabilities.  Reduced GSH and N-acetylcysteine in 100 mM Tris buffer, pH 
7.4, when mixed with a final concentration of 250 µM DPPH● in methanol, were effective in 
reducing the absorbance of DPPH● at 515 nm.  Presumably, GSH and N-acetylcysteine were 
oxidized to disulfides concomitantly with the conversion of DPPH● to reduced DPPH.  When 
present in equimolar amounts to DPPH●, GSH and N-acetylcysteine reduced the radical at rates 
of 24.1 and 29.9 nmoles/min, respectively (Figure 5.3.1).  Both GSH and N-acetylcysteine 
scavenged DPPH● as expected, whereas EdAG was ineffective in reducing DPPH● to reduced 
DPPH.  EdAG scavenged at a statistically significant slower rate (2.8 nmoles/min), suggesting 
that EdAG scavenged radicals by a mechanism different from the sulfhydryl agents, GSH and N-
acetylcysteine.  A two-tailed, unpaired Student’s t-test was used to calculate significant 
differences in reduction rates (*P<0.05 for reactions containing EdAG versus GSH control were 
considered statistically significant).  The results of the DPPH radical reduction experiment were 
similar to the weak or absent reactivity with DPPH● by other N-acyl dehydroalanine compounds 
(12).   
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Figure 5.3.1 Reduction of DPPH radical 
 
5.3.2 Radical scavenging activity of EdAG 
 The reactivity of EdAG with hydroxyl radical was determined by generating ●OH with 
the Fenton reaction in the presence of a spin trap (DMPO or POBN), and EdAG as monitored by 
EPR.  EdAG (0-50 mM) was added to the reaction mixture containing FeSO4, DMPO, and H2O2.  
An obvious decrease in the spin adduct (DMPO-OH●) EPR signal was observed in an EdAG 
concentration-dependent manner, suggesting that EdAG is competing with DMPO for 
scavenging hydroxyl radical (Figure 5.3.2).  A reaction rate constant (kE) of EdAG hydroxyl 
radical scavenging, determined from the signal height ratio of the signals marked with arrows 
(Figure 5.3.2 A/B), was calculated to be 8.41 x 109 M-1s-1, based on equations in the literature 
(14,17).  Figure 5.3.2 shows typical EPR spectra of the Fenton reaction containing 100 mM 
DMPO with 0 mM EdAG (Fig. 5.3.2 A), and 100 mM DMPO with 20 mM EdAG (Fig.5.3.2 B). 
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Figure 5.3.2 EPR Spectrum of Fenton Reaction with EdAG 
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Figure 5.3.3 EdAG-dependent scavenging by EPR 
 
Figure 5.3.3 demonstrates the concentration-dependent reduction in the DMPO-OH● signal by 
EdAG.  The signal heights in Figure 5.3.3 are expressed as means ± SEM with n=3 for each 
group, where a two-tailed, unpaired Student’s t-test was used to calculate significant difference 
(* P value <0.05 for reactions containing EdAG versus control without EdAG).  EdAG was also 
suggested to scavenge superoxide (O2-●) produced by the oxidation of xanthine by xanthine 
oxidase.  A complete disappearance of the DMPO-O2● signal occurred when 20 mM EdAG was 
present (data not shown). 
 Typically, when a radical scavenger is introduced to the Fenton reaction containing 
DMPO, a simple decrease in the DMPO-OH● EPR signal is observed.  When EdAG was the 
scavenger, the presence of other radical species was indicated by additional absorption bands 
labeled with asterisks (Fig. 5.3.2B).  In comparison, the same reaction containing GSH instead of 
EdAG produced no signals other than attenuated DMPO-OH● signals (Fig. 5.3.2C).  EPR 
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simulations were performed using WinEPR simulation software and were based on the EPR 
spectra containing EdAG to aid in the identification of the other radical species present.  
Analysis of hyperfine splitting patterns and simulated EPR spectra were consistent with three 
radical species, consisting of DMPO-OH● and two carbon-centered radical species.  The two 
carbon-centered radical species are proposed to be diastereomers of DMPO-EdAG-OH● 
(compound III in Scheme 5.3.1) based on a comparison to literature spectra of the products of N-
acyl dehydroalanines with hydroxyl radical (17) and EPR simulations performed.  Scheme 5.3.1 
depicts the proposed mechanism of EdAG reaction with hydroxyl radical (I) followed by 
dimerization (II) or subsequent reaction with DMPO (III). 
 
 
Scheme 5.3.1 Proposed Mechanism of Hydroxyl Radical Scavenging by EdAG 
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 Figure 5.3.4 depicts the mechanism of hydroxyl radical trapping by the spin trapping 
agents DMPO (top) and POBN (bottom).  POBN was substituted as the spin trap in an attempt to 
better characterize the carbon-centered radical species.  A different EPR spectrum was obtained 
corresponding to POBN-OH● due to the different hyperfine splitting patterns with POBN 
compared to DMPO (Fig. 5.3.5A).  When EdAG was introduced to the Fenton reaction 
containing POBN, an obvious decrease in the POBN-OH● signal was observed, as well as the 
presence of another radical species indicated by asterisks (Fig. 5.3.5B).  EPR simulations again 
were performed and it was concluded that the other radical species was a carbon-centered radical 
that corresponds with the diastereomeric carbon-centered radicals (III) present in the DMPO-
containing reactions, albeit with POBN substituted for DMPO. 
 
 
 
 
 
Figure 5.3.4 Mechanism of hydroxyl radical trapping 
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Figure 5.3.5 EPR Spectra of Fenton Reaction and POBN with EdAG 
 
 
5.3.3 Mass spectrometric identification of EdAG-hydroxyl radical adduct 
 Mass spectrometry was performed to aid in the identification of the adduct of EdAG and 
●OH.  A Fenton reaction mixture containing both FeSO4 and H2O2 was mixed with EdAG and 
immediately analyzed by LC/MS to provide structural evidence of the hydroxyl radical 
conjugated to EdAG (EdAG-OH● or ESG●; I).  Tandem mass spectrometry (MS/MS) was then 
*
B) 
A) 
*
*
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performed on the major reaction product detected in the ion trap mass spectrometer at m/z 581.  
The molecular weight of the product ion at m/z 581 was consistent with a dimer of hydroxylated 
EdAG (HO-EdAG-EdAG-OH, aka di-γ-glutamylserylglycine; aka ESG dimer; II) and is in 
accordance with the literature that carbon-centered radicals formed via captodative mechanisms 
can dimerize (6). 
 Assignment of the mass spectral fragmentation ions consistent with the loss of water (m/z 
563), two water molecules (m/z 545), and pyroglutamic acid plus water (m/z 434) suggest that 
the dehydroalanine group has reacted with hydroxyl radical forming a serine residue carbon-
centered radical (ESG) that dimerizes into a di-γ-glutamylserylglycine compound (Figure 5.3.6).   
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Figure 5.3.6 Accurate MS/MS spectrum of ESG dimer 
 
 
Scheme 5.3.1 depicts the captodative reaction proposed to occur when EdAG scavenges 
hydroxyl radical forming the serine analog of glutathione radical intermediate (I) that either 
dimerizes (II) or is trapped with DMPO (III).  The mass spectral evidence supports a mechanism 
where ESG● (I) condenses with another I to form a stable ESG dimer (II).   
 Accurate mass spectrometry, performed on a Fourier-transfer mass spectrometer (FT-
MS), calculated the theoretical accurate mass for the chemical formula of the ESG dimer (II) as 
581.20493 amu.  The observed accurate mass spectrum of the dimer from addition of EdAG to 
the Fenton reaction was 581.20474 amu, with a difference of 0.3 ppm.  FT-MS/MS was 
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performed in the accurate mass spectrometer and the resulting product ions were 563.19437 amu, 
545.18389 amu, and 434.15202 amu, which are consistent with the neutral losses of one water 
molecule (18.0106 amu), two water molecules (36.0212 amu), and pyroglutamic acid plus water 
(147.053 amu), respectively.  Thus, the major product formed in the reaction of iron, hydrogen 
peroxide, and EdAG was structurally identified as compound II (Scheme 5.3.1). 
 
5.3.4 Reaction of EdAG with Hydroxyl Radical (●OH) in RAW 264.7 Cells 
 Due to the successful captodative scavenging of ●OH by EdAG in vitro, it was desired to 
apply this in cells.  RAW 264.7 cells were grown overnight in fetal bovine serum (FBS), 
followed by exposure to EdAG for one hour before addition of chromium to induce ●OH 
production intracellularly and DMPO to scavenge ●OH radicals and obtain a control EPR signal.  
EdAG was found to be unable to scavenge hydroxyl radical intracellularly.  There was no 
significant decrease in the DMPO-OH● spin adduct signal in the EPR.  It was hypothesized that 
EdAG might be getting conjugated by GSH upon entering the cell, thus forming GSG and 
eliminating its captodative ability to scavenge hydroxyl radical.  A more plausible explanation 
was that the hydrophilic EdAG was unable to cross the cell membrane into the cell, thus unable 
to scavenge hydroxyl radicals intracellularly. 
 
5.3.5 EdAG Cell Permeability 
 To determine whether EdAG was traversing the cellular plasma membrane, 6 wells of 
500,000 BEAS-2B (bronchial epithelial cells) were plated overnight, then incubated with 100, 
200, or 500 µM EdAG in either PBS or serum free media (SFM) for 1 hour.  After 1 hour, the 
media was removed and analyzed by LC/MS to determine how much EdAG remained, i.e. how 
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much EdAG did not enter cells.  Cells were lysed with 0.5% digitonin for 30 min, centrifuged 
and then analyzed by LC/MS to determine the amount of EdAG in the cytosol.  GSH was 
detected in the aliquots obtained after digitonin, suggesting that the cells were sufficiently lysed 
to release intracellular GSH.  It was determined that no EdAG was present in the cytosol 
fraction, indicating that EdAG did not traverse the plasma membrane.  Figure 5.3.7 shows that 
EdAG is present at each concentration level (100, 200, and 500 µM), when PBS media 
supernatent was run on LC/MS prior cell lysing by digitonin (PBS-sn).  After the 30 min 
exposure to digitonin that lysed cells, the lysate (lys+d, Figue 5.3.6) was run and LC/MS 
detected no EdAG at any concentration level.  The bars corresponding to intracellular EdAG 
after lysis are not visible because there was no detectable EdAG.  This provides an explanation 
as to why EdAG did not scavenge intracellular hydroxyl radicals as detected by EPR.   
 
 
 
Figure 5.3.7 Cell membrane excludes EdAG
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DISCUSSION 
5.4  
 GSH is an abundant cellular antioxidant that scavenges intracellular ROS (18).  In the 
depleted state of GSH during busulfan treatments, other ROS scavengers may play an increased 
role.  N-Acyl dehydroalanine residues have been evaluated for the ability to scavenge hydroxyl 
radical (1,12) due to the reactivity of the electrophilic dehydroalanine moieties.  In addition to 
EdAG, there are numerous examples of low molecular weight compounds containing 
dehydroalanine moieties that are able to scavenge ROS such as hydroxyl (●OH) and superoxide 
(O2-●) radical, as well as reducing lipid peroxidation (1,4,7-12,17,19).   
 As is the case for N-acyl dehydroalanine esters, compounds operating though a 
captodative mechanism would not be expected to reduce DPPH radical due to the lack of a 
redox-active thiol group present in GSH.  Consistent with other dehydroalanines (12), EdAG did 
not scavenge DPPH●, which suggests that EdAG is not a redox-based scavenger.  Thus, EPR and 
mass spectrometry (MS) were used to determine the mechanism by which EdAG scavenges 
radicals. 
 EdAG scavenged ●OH generated in the Fenton reaction as shown by attenuation of the 
EPR signal from spin-trapped radicals with DMPO (Figure 5.3.2).  EdAG also significantly 
attenuated the DMPO-O2● signal (data not shown), suggesting that EdAG also scavenged 
superoxide as has been observed for other dehydroalanine scavengers of ROS (1).  The radical 
intermediate formed, EdAG-OH● (γ-glutamylserylglycine; I), stabilizes the free radical on the α-
carbon of the resulting serine residue, where it is too unreactive to attack the alkene of another 
EdAG, and in a recombination reaction, dimerizes to form compound II.  The rate of the 
concentration-dependent scavenging of ●OH by EdAG (kE) was calculated as 8.41 x 109 M-1s-1.  
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This rate is comparable to the scavenging rate constant of the N-acyl dehydroalanine AD-5 of 4.5 
x 109 M-1s-1 (17) and of the redox active resveratrol 9.45 x 108 M-1s-1 (14).  The presence of 
additional radical species in Figure 5.3.2B was consistent with literature (17) and EPR 
simulations were performed to better characterize those radical species.  Based on the known 
hyperfine splitting patterns for DMPO-OH● (aN ≅ aH ≅ 14.9 gauss), there were two additional 
radical species suggested to be present with hyperfine splittings consistent with aN > aH, which 
indicated carbon-centered radicals.  Further analysis of the simulation results revealed that the 
two carbon-centered radicals present resembled diastereomers of the same compound, suggested 
to be compound III from Scheme 5.3.1.   
 A second spin trap, POBN, was used to further characterize the hydroxyl radical 
scavenging properties of EdAG and assess the validity of diastereomers of spin traps adducted to 
compound I.  The use of a different spin trap aside from DMPO could help differentiate each 
carbon-centered radical species by EPR.  Figure 5.3.5B does show the presence of another 
radical species (other than POBN-OH●) as indicated by asterisks, but EPR simulations 
determined there to be only one carbon-centered radical species present, not two as the case 
when DMPO was the spin trap.  It was concluded that both spin traps adduct compound I at a 
chiral center, however POBN produces only one carbon-centered radical species detectable by 
EPR whereas DMPO produces diastereomers of the same carbon-centered radical species.  
Alternatively, POBN could be producing diastereomers that have signals that are superimposed. 
 Mass spectrometric identification of the dimer (II) as a product in the Fenton reaction 
with EdAG supports the indication that a captodative radical intermediate is likely to be formed 
in the reaction of EdAG with hydroxyl radical (Scheme 5.3.1).  Spin traps (DMPO, POBN) were 
excluded from these experiments so to not produce spin trapped carbon-centered radicals, thus 
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leaving only the EdAG-hydroxyl radical product.  Confirmation of the structure was performed 
by FT-MS/MS for accurate mass neutral loss, where II lost fragments of water and pyroglutamic 
acid.  Pyroglutamic acid is a common neutral loss for GSH-containing compounds when 
analyzed by ESI-MS/MS (20,21).  The simplicity of the MS/MS product ion spectrum of II (di-
γ-glutamylserylglycine) as shown in Figure 5.3.6 suggests a symmetrical compound. 
 A mechanism involving an energetically favorable captodative radical is a plausible 
explanation for the Michael addition of hydroxyl radical to EdAG to form a carbon-centered 
radical on the α-carbon of the dehydroalanine moiety.  This captodative, or push-pull radical (5), 
is stabilized by resonance associated with electron donation by the adjacent nitrogen atom, and 
delocalization through the electron-withdrawing carbonyl group.  This reactive radical (I) can 
condense with a second radical to form an ESG dimer (II), or can be trapped with DMPO (III).  
The dimerization is in accordance with previous studies involving hydroxyl radical and 
dehydroalanine-containing compounds (6).  It is interesting to note that the captodative 
mechanism for scavenging radicals is different from the scavenging ability of sulfur-containing 
compounds, most notably GSH and N-acetylcysteine, which involve thiyl radical intermediates 
in a redox mechanism.   
 Because in vitro experiments were successful in determining the ability of EdAG to 
captodatively trap hydroxyl radical, it was desired to apply this to a physiological setting to 
determine if EdAG, when formed inside hepatocytes during busulfan metabolism, is able to 
scavenge hydroxyl radicals intracellularly.  During high-dose busulfan administration, GSH can 
become depleted, leaving the cell vulnerable to ROS.  EdAG could potentially play a protective 
role by scavenging ROS.  EdAG was not shown to decrease the hydroxyl radical signal.  When 
further investigated as to why this occurred, it was hypothesized that the hydrophilic EdAG was 
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not capable of crossing the cell membrane.  EdAG is a GSH analog and there are no cellular 
GSH importers because each of the three individual amino acids (glutamate, cysteine, glycine) 
are assembled intracellularly.  Following this rationale, the cell permeability of EdAG was tested 
on a bronchial epithelial cell line, which was chosen because of its accessibility (plated cells 
were courtesy of George Medan).  After a 1 hour incubation of EdAG with plated BEAS cells, 
there was no intracellular EdAG detected by LC/MS.  The hydrophilic nature of EdAG is 
suggested to prohibit the intact molecule from freely crossing the cell membrane, and thus from 
scavenging intracellular hydroxyl radical. 
 In conclusion, it was demonstrated in this chapter that the dehydroalanine-containing 
EdAG can scavenge hydroxyl radical by a captodative mechanism that is in agreement with 
literature references for other dehydroalanine-containing compounds.  EdAG induced a 
concentration-dependent scavenging of hydroxyl radical as monitored by EPR.  The radical 
product was structurally identified by mass spectrometry.  Physiologically, this is relevant 
because as busulfan is metabolized by GSH conjugation to form EdAG, numerous mechanisms 
contribute to the depletion of intracellular glutathione.  Glutathione plays an essential role as a 
cellular redox buffer and its depletion could increase oxidation by ROS.  The transformation of 
GSH to EdAG represents the loss of thiol-related redox scavenging but the addition of a 
captodative scavenging mechanism.  Thus, EdAG is formed intracellularly and hypothetically is 
present to scavenge intracellular hydroxyl and superoxide radicals in the cytosol.  The scope of 
this research did not extend to inducing ROS production in hepatocytes while metabolizing 
busulfan to form EdAG. 
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Advisor: Cindy Samet, Ph.D. Associate Professor of Chemistry 
 
RESEARCH FOCUS: 
• The reactivity of a specific metabolite of the anticancer drug busulfan, which is an electrophilic 
dehydroalanine analog of glutathione.  Determining the mechanisms by which this metabolite 
induces toxicity by studying enzyme inhibition and conjugation with endogenous nucleophiles, 
free radicals, and the enzyme it inhibits 
• Pharmacokinetics of the chemotherapeutic agent 5-fluorouracil and its oral prodrug tegafur in 
Phase I clinical trials using validated high-performance liquid chromatography/tandem mass 
spectrometry (LC/MS/MS) 
 
RESEARCH SKILLS:  
• Extensive experience with HPLC, MS, LC/MS, and UV spectrophotometry 
• Method validation for LC/MS/MS 
• Pharmacokinetic analysis of patient plasma samples with a validated LC/MS/MS method 
• Hands on experience with matrix-assisted laser desorption ionization (MALDI) mass 
spectrometry, electron paramagnetic resonance (EPR) and nuclear magnetic resonance (NMR) 
spectroscopy 
 
CERTIFICATIONS/LABORATORY TRAINING:  
• HIPAA, West Virginia University, Morgantown WV 26506 
• WVU Animal Welfare Training according to the IACUC, October 2005, West Virginia 
University, Morgantown, WV 26506 
• Scientific Ethics Training (Fall 2005) 
 
AWARDS/SCHOLARSHIPS:  
• E.J. Van Liere Memorial Research Convocation and Research Day (WVU Health Sciences) - 
$100 award for oral presentation in April 2009 
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• WVU School of Pharmacy, Pharmaceutical and Pharmacological Sciences Graduate Student 
Research award - $250 awarded in April 2009 
• Robert E. Stitzel Graduate Student Support Fund (WVU School of Pharmacy) – Research and 
Scholarship Productivity Award:  $1,000 award granted in September 2008 
• Society of Forensic Toxicologists (SOFT) Educational Research Award:  $1,000 travel award 
granted in May 2007 for the October 2007 Annual National Meeting in Raleigh-Durham, NC 
• Pennsylvania Higher Education Assistance Agency (PHEAA), New Economy Technology 
Scholarship (NETS), SciTech Scholarship: $3,000 grant awarded in 2002, 2003 and 2004 
 
PROFESSOINAL EXPERIENCE: 
June – August 2005 and May – August 2004 
Mylan Pharmaceuticals, Morgantown, WV. Sponsor: Scott Chervenick, Ph.D. 
Prepared clinical plasma samples for bioanalytical analysis by HPLC and MS, as well as reagents, 
solutions, and mobile phases used in HPLC and MS. 
 
August – December 2004 
Department of Chemistry, Dickinson College, Carlisle, PA.  Lab of Michael Holden, Ph.D. 
Synthesized ferrocene-containing analogs, analyzed by NMR, to study iron analogs of the anti-malarial 
drug proguanil. 
 
June – August 2003 
Center for Pharmaceutical Technology, Mylan School of Pharmacy, Duquesne University, Pittsburgh, 
PA.  Sponsor: Carl Anderson, Ph.D. 
Assisted graduate students in projects consisting of using Near-Infrared (NIR) imaging to determine the 
composition of pharmaceutical compacts. 
 
PROFESSIONAL MEMBERSHIPS: 
• International Society for the Study of Xenobiotics (ISSX) (June 2008-Present) 
• Society of Forensic Toxicologists (SOFT) (May 2007-Present) 
• American Society for Mass Spectrometry (ASMS) (November 2006-Present) 
• Gamma Sigma Epsilon Chemistry Honor Society, Rho Zeta Chapter, Dickinson College, Carlisle, 
PA 17013 (May 2004) 
 
PUBLICATIONS:  
Leonard SS, Hogans VJ, Coppes-Petricorena Z, Peer CJ, Vining TA, Fleming DW, and Harris GK. 
Analysis of Free Radical Scavenging of Yerba Mate (Ilex paraguriensis) using Electron Spin Resonance 
and Radical-induced DNA Damage. J Food Science. 00: C1-C7 (2009). 
 
Miranda L. Hanson, Cody J. Peer, Rodney Brundage, Patrick Callery, Kathleen Brundage, Rosana 
Schafer, Sergei Eremin, and John B. Barnett.  Subcellular localization of the amide class herbicide 3,4-
dichloropropionanilide (DCPA) in T cells and hepatocytes.  J. Tox. Envir. Htl. Part A: 73(1):1-4 (2009). 
 
Erinne R. Dabkowski, Courtney L. Williamson, Valerie C. Bukowski, Rebecca S. Chapman, Stephen S. 
Leonard, Cody J. Peer, Patrick S. Callery, and John M. Hollander.  Diabetic Cardiomyopathy-Associated 
Dysfunction in Spatially Distinct Mitochondrial Subpopulations Am J Physiol Heart Circ Physiol. 
296(2):H359-69 (2009). 
 
Islam R. Younis, Meenal Elliott, Cody J. Peer, Arthur J.L. Cooper, John T. Pinto, Gregory 
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W. Konat, Michal Kraszpulski, William P. Petros, and Patrick S. Callery.  Dehydroalanine analog of 
glutathione: An electrophilic busulfan metabolite that binds to human glutathione S-transferase A1-1.  J. 
Pharmacol Exp Ther. 327(3): 770-6 (2008). 
 
Cody J. Peer, David J. Clay, Heather L. Glover, Kristina L. Renninger, James C. Kraner, and Patrick S. 
Callery.  Direct Injection Mass Spectrometric Confirmation of Multiple Drugs in Overdose Cases from 
Postmortem Blood using ESI-MS/MS and MS3.  J. Anal. Toxicol. 32(8): 709-714 (2008). 
 
Cody J. Peer, Diaa M. Shakleya, Islam R. Younis, James C. Kraner, and Patrick S. Callery.  Direct-
Injection Mass Spectrometric Method for the Rapid Identification of Fentanyl and Norfentanyl in 
Postmortem Urine of Six Drug-Overdose Cases. J. Anal. Toxicol. 31(8): 515-520 (2007). 
 
ABSTRACTS:  
Cody J. Peer, Islam R. Younis, Valerie C. Bukowski, Stephen S. Leonard, William P. Petros, and Patrick 
S. Callery.  Gamma-Glutamyldehydroalanylglycine is an Unusual Metabolite of Glutathione that Inhibits 
Glutathione S-Transferase Activity and Reacts with Hydroxyl Radical by a Captodative Mechanism.  
Accepted for poster presentation at the 16th Annual North American Regional Meeting of the International 
Society for the Study of Xenobiotics (ISSX), October 19-21, 2009, Baltimore, MD. 
 
Cody J. Peer, Steven S. Leonard, and Patrick S. Callery.  Properties of a Dehydroalanine Analog of 
Glutathione: A Novel Busulfan Metabolite.  Presented as an oral and poster presentation at the 2009 West 
Virginia University Health Sciences Van Liere Research Day.  April 27-28, 2009. 
 
William Petros, Mukur Gupta, Vincenzo Guarcello, Thomas McIntire, Terrance McManus, Cody Peer, 
Gerry Hobbs, Scot Remick, William Peters. Preclinical development of a topical eniluracil formulation 
for prevention of fluropyrimidine-induced hand foot syndrome (abstract).  American Association for 
Cancer Research, Dec. 2, 2008. 
 
Cody J. Peer, Islam R. Younis, and Patrick S. Callery. Formation of a Non-Reducible Lanthionine 
Thioether from Glutathione and a Busulfan Metabolite (Poster). Presented as a poster at the 15th Annual 
North American Regional Meeting of the International Society for the Study of Xenobiotics (ISSX), 
October 12-16, 2008, San Diego, CA. 
 
Islam R. Younis, Cody J. Peer, Meenal Elliot, Arthur J. L. Cooper, John T. Pinto, Gregory W. Konat, 
William P. Petros, and Patrick S. Callery. Dehydroalanine Analog of Glutathione: An Electrophilic 
Busulfan Metabolite that Binds to Human Glutathione-S-Transferase A1-1.  Presented in an oral format at 
the 41st Annual Mid-Atlantic Graduate Student Symposium in Medicinal Chemistry (MAGSS), July 20-
22, 2008, Wayne State University, Detroit, MI. 
 
Miranda L. Hanson, Cody J. Peer, Kathleen Brundage, Rosana Schafer, Sergei A. Eremin, and John B. 
Barnett.  Subcellular Localization of the Amide Class Herbicide 3,4-Dichloropropionanilide (DCPA) in T 
Cells.  Presented as a poster at the 47th Annual Meeting of the Society of Toxicology, March 16-20, 2008, 
Seattle, WA. 
 
Cody J. Peer, Diaa M. Shakleya, Islam R. Younis, James C. Kraner, and Patrick S. Callery.  Direct-
Injection Mass Spectrometric Method for the Rapid Identification of Fentanyl and Norfentanyl in 
Postmortem Urine of Six Drug-Overdose Cases. Presented as a poster at the Society of Forensic 
Toxicologists (SOFT) Annual Meeting, October 14-19, 2007, Chapel Hill, NC. 
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Jirapan Moungjaroen, Islam R. Younis, Cody J. Peer, Ubonthip Nimmannit, Yon Rojanasakul, and 
Patrick S. Callery. Mechanism of Lipoic Acid Protection from Cisplatin-induced DNA Damage Using 
HPLC and Mass Spectrometry. Presented as a poster at the 40th Annual Mid-Atlantic Graduate Student 
Symposium in Medicinal Chemistry (MAGSS), June 10-12, 2007, West Virginia University, 
Morgantown, WV. 
 
Cody J. Peer, Diaa M. Shakleya, Islam R. Younis, James C. Kraner, and Patrick S. Callery.  Direct-
Injection Mass Spectrometric Method for the Rapid Identification of Fentanyl and Norfentanyl in 
Postmortem Urine of Six Drug-Overdose Cases. Presented as a poster at the  55th Annual Meeting of the 
American Society for Mass Spectrometry (ASMS), June 3-7, 2007, Indianapolis, IN.  
 
Cody J. Peer, Patrick S. Callery, James C. Kraner, and Diaa M. Shakleya. Identification of 8 Drugs in 15 
Minutes from Postmortem Urine by Direct Infusion MS/MS. Case Note published in May 2007 Issue of 
ToxTalk, part of the Society of Forensic Toxicologists. 
 
Diaa M. Shakleya, James C. Kraner, Cody J. Peer, and Patrick S. Callery.  Identification of Fentanyl in 
Urine from Drug Abuse Cases Using a Direct Multistage Mass Spectrometry Method. Presented as a 
poster at the 39th Annual Mid-Atlantic Graduate Student Symposium in Medicinal Chemistry (MAGSS), 
June 18-20, 2006, Ohio State University, Columbus, OH. 
 
Carl Anderson, David Molseed, Cody J. Peer.  Quantitative Imaging of Pharmaceutical Compacts.  
Duquesne University, Center for Pharmaceutical Technology (DCPT), Pittsburgh, PA.  Presented at the 
2004 IFPAC/PAT meeting on January 14, 2004. 
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